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CHAPTER 1: INTRODUCTION
I. Breast cancer disparities: mortality and tumor biology
Breast cancer is the most common cancer and second leading cause of death for women
in the United States1. Although breast cancer incidence is equal among European American and
African American women, African American women are especially burdened with a 42% higher
breast cancer mortality rate2. The underlying causes of this survival disparity are still debated and
have been partially attributed to social determinants including differential environmental exposure,
access to care and quality of care issues3–6. Breast cancer stage of diagnosis further contributes
to this disparity as African American women are not only more likely to be diagnosed with breast
cancer at later stage disease, but their 5-year survival is lower than that of other ethnic groups at
every stage7.
Consistent reports that African American women suffer higher rates of young-onset breast
cancer – cancer diagnosed before the age of 35 that is additionally associated with more
aggressive disease – than women of all other ethnic groups point to differences in tumor biology8–
10

. Molecular grading and subtyping furthered this understanding. Even after adjusting for age and

stage of disease, African American women are more likely to have high-grade tumors11,12. They
are also more likely to be diagnosed with aggressive subtypes characterized by the lack of
hormone receptors which are resistant to hormone therapy and marked by poorer survival9,11,12.
Genetic profiles of stage I-III breast tumors in The Cancer Genome Atlas (TCGA) indicate more
aggressive and recurrent tumors in African American women: these show higher intratumoral
genetic heterogeneity, more basal-like (PAM50) signatures, and more TP53 mutations than
tumors from European American women13. Transcriptional profiles of stage I-III breast tumors in
TCGA also suggest differences by race. Resistin, associated with insulin resistance and obesity,
is upregulated while LOC90784, a long non-coding RNA inversely associated with breast cancer
stage and the triple negative subtype, is downregulated in tumors from African American women
compared to tumors from European American women14. As our understanding of cancer biology
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progresses, it is likely that additional mechanisms will be identified that contribute to racial
differences and disparities in breast cancer.
II. Breast cancer risk factors
Breast cancer risk factors and risk models
Our understanding of breast cancer risk factors can be synthesized with breast cancer risk
models such as the Gail model, more commonly known as the National Cancer Institute’s Breast
Cancer Risk Assessment Tool (BRCAT)15. This tool incorporates information from several risk
factors including estrogen exposure, family history and prior biopsy history. Risk models provide
patients, physicians and scientists estimates of absolute risk of developing breast cancer over a
specified period, typically over the next five years or total lifetime. BRCAT can be used clinically
to identify women at high risk who may benefit from increased screening for early detection of
breast cancer or chemoprevention to reduce breast cancer risk.
Although useful, breast cancer risk models do not discriminate between women destined
to develop or not to develop breast cancer with a high degree of accuracy. The ability to separate
patients who are destined to become cases from controls is typically measured by the area under
the receiver operator characteristic curve (AUC). The BRCAT has an AUC of 0.6 – a low to
moderate level of discriminatory accuracy16. Risk model discriminatory accuracy can be improved
by adding risk factors that capture new biologic information that reflect breast cancer risk or
carcinogenesis. Models that have incorporate additional biological information not already
captured by the BRCAT such as mammographic density and genetic SNP scores perform better
with an AUC around 0.6816; however, the moderate level highlights the clear need to identify new
biological risk factors to improve breast cancer risk assessment.
The BRCAT model was created using risk factors estimated from primarily European
American women populations, and the use of this tool in African American women is limited as
the model underestimates breast cancer risk in this population17. The Gail model was modified
for use in African American populations using the Women’s Contraceptive and Reproductive
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Experiences (CARE) Study. Unfortunately, this model still underestimates breast cancer risk for
African American women with a prior breast biopsy17–19. Risk models for this population can
improve by providing robust, race-specific risk factor estimates from cohort studies.
Current breast cancer risk models primarily estimate the risk of developing ER positive
breast cancer over a specified period. Model accuracy could improve with the addition of ER
negative or subtype-specific models. Several studies indicate that risk factors can vary in strength
by breast cancer subtype20–23. As ER-negative and triple-negative breast cancers are more
prevalent in African American women1,9,12, African American women may be especially poised to
benefit from subtype-specific models. Further incorporation of other biological variables that are
more prevalent in African American women, such as obesity, may also improve risk models in this
population.
Obesity and breast cancer risk
Obesity, or excess body fat, has long been associated with breast cancer and is more
prevalent in the African American population, but this association is altered by menopausal status.
Obesity is associated with a reduced breast cancer risk in premenopausal women but an
increased breast cancer risk in postmenopausal women24,25. This conflicting risk is thought to be
due to the influence of obesity on the hormonal milieu of patients. Estrogen exposure is highly
associated with hormone receptor positive breast tumors26. In premenopausal women, excess
body fat is associated with anovulatory or irregular menstrual cycles and lower circulating
estrogen levels27, subsequently leading to a decrease in breast cancer risk. Postmenopausal
women not receiving hormone replacement therapy have low circulating levels of estrogen, so
the aromatization of androgens to estrogens in excess adipose tissue can significantly increase
estrogen levels that lead to increased risk of hormone receptor positive tumors26,28. As most breast
cancers develop in post-menopausal women and are hormone-receptor positive, obesity is an
important risk factor for breast cancer.
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Estrogen receptor (ER) negative and triple negative tumors occur more frequently in
premenopausal obese women compared to premenopausal normal weight women29,30. These
tumors are generally more aggressive and have a poorer prognosis31. Though these tumors lack
estrogen receptors, estrogen may play a role in pathogenesis. Patients with BRCA1- or BRCA2
mutations undergoing prophylactic oophorectomy, which effectively lowers total estrogen
exposure, results in significant reduction of estrogen receptor negative breast cancer risk in both
pre- and post-menopausal women32. Other mechanisms that may contribute to the risk increase
associated with obesity are increased insulin on the Akt/mTOR signaling pathway, the release of
inflammatory cytokines, and changes to the breast tissue microenvironment33.
African American women experience an obesity prevalence about 50% higher than
European American women, and 70% higher for women under the age of 4034. This increase in
obesity may contribute to the increased incidence of young-onset and estrogen receptor negative
breast cancers in African American women. In African Americans, an increased waist-to-hip ratio
is also associated with triple negative tumors in both pre- and post-menopausal women35.
Increased waist-to-hip ratio is associated with a visceral fat distribution where fat surrounds the
abdominal organs. Visceral fat is associated with higher rates of metabolic syndrome,
inflammation, and postmenopausal breast cancer36.
Benign breast disease and the subsequent risk of breast cancer
Approximately 1.6 million breast biopsies are performed each year in the United States37,
and most result in non-malignant findings, or benign breast disease (BBD). Though these
pathologies are not malignant, the presence of BBD on biopsy is associated with increased risk
of developing in situ or invasive breast cancer38. BBD lesions can be categorized by Dupont and
Page criteria for the presence of epithelial proliferation and atypical cells as these two
characteristics confer higher risk of subsequent breast cancer in several cohorts of European
American women38,39. BBD features are heterogeneous for breast cancer risk: columnar
alterations, or morphological changes in the breast epithelium, are associated with increased risk
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while lobular involution, or atrophy of fibroglandular breast tissue, is associated with decreased
risk38,40.
BBD has not been well studied in African American women as the majority of studies were
conducted in European American populations. Worsham et al41,42 included African American
women in their analysis of BBD and breast cancer, but the sample size was limited and studied
retrospectively. There is evidence that BBD presents differently in African American women fibroadenomas, benign tumors of stromal and epithelial tissue, occur and recur more frequently
in African American women than European American women43. As BBD may present differently
in African American women, further study of BBD is imperative in this population to identify women
who are at high risk of developing in situ or invasive breast cancer.
Breast density and breast cancer risk
Breast density describes the appearance of breast tissue on mammogram – fibroglandular
tissue appears dense or radiopaque and adipose tissue appears non-dense or radiolucent. Both
qualitative and quantitative assessments of breast density are strongly associated with breast
cancer risk44–46. Dense tissue areas on mammograms are associated with location47 and hormone
receptor status48 of subsequently arising cancer. Dense areas on mammogram can also mask
small tumors, delaying cancer diagnosis.
The majority of breast density studies were conducted in European American or European
populations and has not been well studied in African American women. The multi-center Breast
Cancer Screening Consortium49 included about 2800 African American women, but as this
constituted around only 6% of study participants, did not provide race-specific estimates for breast
cancer risk. Other studies have suggested differences by race50 and McCarthy et al51 found that
African American women were more likely to have dense breasts than European American
women once adjusting for age and BMI. Additionally, very few studies49,52 have been able to
examine breast density in women with BBD. Assessing both density and BBD is important to
understanding how these factors may modify or interact relationships with breast cancer risk.

6
III. Rationale
This dissertation examines radiologic and pathologic tissue-based risk factors for breast
cancer in African American women, an underserved population experiencing increasing breast
cancer incidence and high mortality burden. Ultimately, we hope to improve risk estimation in this
population for better clinical management, to prevent or detect breast cancers earlier to improve
breast cancer survival. The importance of breast cancer risk factors is not limited to absolute risk
estimates: risk factors can also reveal information about breast carcinogenesis. Long-term goals
of this dissertation are to further our understanding of breast carcinogenesis in African American
women and find features that may predict breast cancer in this population. In this dissertation, we
characterize several known and previously not described risk factors on mammograms and
pathology tissue from the Detroit BBD cohort to provide race-specific risk factor estimates and
new biological information to improve breast cancer risk models in African American women.
The Detroit BBD cohort53 comprises African American women aged 18 to 84 diagnosed
with BBD between 1997 and 2010 in the metropolitan Detroit area. Women with a history or
diagnosis within six months of invasive or in situ breast carcinoma were excluded from this
Institutional Review Board approved study. Breast biopsy tissue was examined by study
pathologists for Dupont and Page criteria39 and individual BBD lesions. In situ and invasive breast
carcinomas were ascertained by linkage to the Metropolitan Detroit Cancer Surveillance System
(MDCSS), a founding member of the National Cancer Institute’s Surveillance Epidemiology and
End Results (SEER) program. This dissertation utilizes the strengths of this existing BBD cohort
and biospecimens to further characterize current and novel breast cancer risk factors in African
American women. As tissue reflects both genetic and environmental determinants of disease, this
is a valuable resource to understand breast cancer risk.
The specific aims of the dissertation were:
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1. To determine whether risk of subsequent breast cancer associated with
fibroadenomas on benign breast biopsy in African American women differs from
European American women.
2. To characterize the association between qualitative density and parenchymal patterns
on mammographic images and breast cancer.
3. To examine whether crown-like structures on benign breast biopsy were associated
with breast cancer risk.
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CHAPTER 2: BREAST FIBROADENOMAS ARE NOT ASSOCIATED WITH SUBSEQUENT
BREAST CANCER RISK IN AN AFRICAN AMERICAN COHORT
I. Introduction
Over 1.5 million breast biopsies are pathologically assessed annually in the United States,
indicated by abnormal mammography findings or patient complaints37. Most biopsies are not
malignant, but instead exhibit a number of pathological lesions that constitute benign breast
disease (BBD). Biopsies that exhibit proliferative disease or cellular atypia, as defined by Dupont
and Page criteria, are consistently associated with increases in breast cancer risk 38,39,53. These
pathologic criteria have been included in risk assessment models to identify women at high risk
of developing breast cancer. Several current risk assessment models, including the frequently
used Breast Cancer Risk Assessment tool, incorporate information on the number of prior
biopsies and the presence of atypia, but do not account for other BBD lesions that may
independently increase breast cancer risk15. Reliable estimates of breast cancer risk associated
with individual lesions can improve risk models, allowing physicians to better identify women at
high risk of developing breast cancer who may benefit from additional screening or
chemoprevention.
One type of BBD, fibroadenomas, are well-circumscribed benign tumors of epithelial and
stromal tissue54 (Figure 1). Breast fibroadenomas most frequently occur in women in their 20s 54
but can occur at any age; it is estimated that 10% of women have breast fibroadenomas 55. A
recent meta-analysis of 11 studies reported an increase in breast cancer risk by 41% (95% CI:
11-80%) for women diagnosed with a fibroadenoma compared to women without fibroadenoma
on biopsy; however, this estimate exhibits significant statistical heterogeneity56. Furthermore, the
studies in this meta-analysis were primarily from European ancestral populations, and several
were conducted prior to the widespread use of screening mammography in the 1980s. Although
African American women experience a higher incidence and recurrence of fibroadenomas at a
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younger age43,57, breast cancer risk associated with this lesion has not been independently
assessed in this population of women.

Fig. 1 Fibroadenoma. Fibroadenomas are benign tumors of stromal and epithelial tissue that are
typically well-circumscribed and mobile within the tissue. The fibroadenoma shown here exhibits purple
epithelial tissue surrounded by pink fibrotic stromal tissue (hematoxylin-eosin; original magnification 100x)

African American women suffer a 42% higher breast cancer mortality rate than European
American women2, a burden that partly stems from differences in tumor biology. African American
women are more likely to develop breast cancer at a younger age8–10 and more likely to be
diagnosed with aggressive tumors characterized by high molecular grade11,12 and lack of hormone
receptors9,11,12. Despite this survival disparity, prior investigations on BBD and breast cancer risk
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focused on primarily European American cohorts. A study cohort from Henry Ford Hospital in
Detroit was the first to include a considerable number (1200+) of African American women41,42,58,
but studies in African American women are largely lacking. The goal of this study is to examine in
a contemporary cohort whether breast cancer risk associated with fibroadenoma differs for African
American women, a population who are more likely to present with fibroadenomas and more likely
to develop aggressive breast cancers that respond poorly to treatment.
II. Materials and Methods
Study design
We conducted a retrospective cohort study to investigate the subsequent breast cancer
risk associated with a fibroadenoma on biopsy. This cohort consists of African American women
diagnosed with BBD between 1997 and 2010 in metropolitan Detroit who were passively
followed for breast cancer current to December 2015. Our main exposure of interest was the
presence or absence of fibroadenoma on biopsy; our main outcome of interest was the
diagnosis of in situ or invasive breast carcinoma.
We first identified which features were more common by presence or absence of
fibroadenoma on biopsy. In our analyses of associated breast cancer risk in this cohort, we
adjusted for likely confounders including age and previously identified categorizations of BBD:
epithelial proliferation and cellular atypia. To understand this breast cancer risk in the context of
population level risk, we finally compared in situ and invasive breast carcinoma incidence in this
cohort to that of the larger metropolitan Detroit population.
Study population
African American women with their first benign breast biopsies conducted between 1997
and 2010 were identified using University Pathology Group (UPG; Detroit, MI) records. UPG
provides pathology services to hospitals in metropolitan Detroit including Sinai Grace, Harper
Hospital, and Karmanos Cancer Institute. Women aged 18 to 84 at time of benign breast biopsy
were eligible for this Institutional Review Board approved study. Exclusionary criteria included: a
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diagnosis of invasive or in situ breast carcinoma before or within six months of the breast biopsy,
a history of mastectomy or reduction mammoplasty, lipoma, fat necrosis, epidermal cysts,
hematoma, accessory structure, phyllodes tumor, or a lymph node biopsy without breast tissue.
For this type of study, the Wayne State University Institutional Review Board determined that
written informed consent was not required. Data on age at biopsy, date of birth and date of biopsy
for all women in this cohort were collected for this study.
Histology review
Core needle and excisional benign biopsies were microscopically reviewed by blinded
study pathologists using original hematoxylin and eosin (H&E) slides. Slides from the first biopsy
were assessed for the presence of BBD lesions and lobular involution similar to the Mayo Clinic’s
BBD study38. In total, 12 pathologic lesions including apocrine metaplasia, calcifications, columnar
alterations, cysts, duct ectasia, ductal hyperplasia, fibroadenoma, fibrosis, intraductal papilloma,
lobular hyperplasia, radial scars, and sclerosing adenosis were assessed. A biopsy could indicate
the presence of one or multiple lesions.
The biopsies were additionally categorized into three groups using criteria described by
Dupont and Page39 to control for the presence of proliferative disease and cellular atypia,
previously shown to be strongly associated with breast cancer risk. Biopsies were categorized as
non-proliferative disease if these included only fibroadenoma, cysts, fibrosis, ductal ectasia, mild
ductal hyperplasia, mild lobular hyperplasia, apocrine metaplasia, radial scars, calcifications,
and/or columnar alterations. Biopsies that also included intra-ductal papilloma, sclerosing
adenosis, moderate to florid ductal hyperplasia, moderate to florid lobular hyperplasia and/or
columnar alterations with hyperplasia were categorized as proliferative disease. Biopsies that
included atypia (in addition to ductal hyperplasia, lobular hyperplasia, fibroadenoma and/or
columnar alterations) were categorized as proliferative disease with atypia.
Biopsies classified as showing atypia and a random sample of all other biopsies were reassessed by a blinded study pathologist at the Mayo Clinic. Breast biopsies that could not be
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assessed for fibroadenoma presence due to limited tissue were excluded from analysis (N=23).
Data on the presence or absence of the pathologic lesions, proliferative disease and cellular
atypia were collected for this study.
In situ and invasive carcinoma ascertainment
Women who developed in situ or invasive breast carcinoma were identified through
hospital medical records and also through the use of the Metropolitan Detroit Cancer Surveillance
System (MDCSS), a founding member of the National Cancer Institute’s Surveillance
Epidemiology and End Results (SEER) program for more complete follow-up. MDCSS collects
cancer incidence, treatment and survival data in the tri-county metropolitan Detroit area.
Utilization of both data sources allowed the identification of cancers in women residing in the
entire tri-county metropolitan Detroit area. Women were matched between UPG records and
MDCSS using name, date of birth, and/or social security number; follow-up information was
complete to December 31, 2015. Data on the diagnosis of in situ or invasive breast cancer, date
of diagnosis and vital status were collected for this study.
Statistical Analysis
Our first objective was to examine whether fibroadenomas were associated with other
benign lesions on biopsy; we evaluated these associations using chi-square tests. Our second
objective was to examine the risk of breast cancer associated with fibroadenomas relative to other
non-fibroadenoma BBD. This objective was evaluated within the Detroit cohort using relative risk
ratios and 95% confidence intervals calculated using multivariable log-binomial regression and
adjusting for age at biopsy. Regression models were further adjusted with the Dupont and Page
criteria (epithelial proliferation and cellular atypia on biopsy), likely confounders consistently
identified in prior studies of BBD, and backwards selection based on Bayesian information
criterion (BIC) to fully adjust analyses for other potential confounders. Our third objective was to
examine whether breast cancer risk associated with fibroadenoma presence on biopsy differed
by likely menopausal status; we evaluated this risk difference by stratifying the regression models
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by age (below or above 50 years). Our fourth objective was to examine whether the time to breast
cancer diagnosis differed by fibroadenoma presence on biopsy. We evaluated this time to
diagnosis using competing risk analysis with death due to any cause other than breast cancer
considered as a competing risk.
Our last objective was to examine the excess risk of breast cancer associated with having
a biopsy, with or without fibroadenoma, compared to that of the general population. We estimated
this excess risk using age-adjusted standardized incidence ratios (SIRs) calculated from SEER
estimates of in situ and invasive breast cancer incidence in African American women in MDCSS
from 1999 to 2015.
III. Results
Distribution of BBD features and characteristics by fibroadenoma status
3,845 benign breast biopsies were assessed in this African American cohort, 1,798 (47%)
of which were diagnosed with fibroadenoma. Median length of follow-up was 13.0 years (range
0.5 – 19.0 years); median time to breast cancer diagnosis was 7.3 years (range 0.7 – 18.5 years).
Fibroadenomas showed high concordance between study pathologists from KCI and the Mayo
clinic (86.9%; Cohen’s κ = 0.7022, Table 1) and the highest Cohen’s κ of all BBD lesions described
on biopsy.

Table 1. Inter-observer agreement on fibroadenoma presence between study pathologists in a
subset of the Detroit Benign Breast Disease cohort, 1997-2010
KCI b read
N (%)
Absent
Present
Total
Absent
92 (63.89%)
6 (4.17%)
98
Mayo a
read

aMayo

Present

12 (8.33%)

34 (23.61%)

46

Total

104

40

144c

pathologist Daniel W. Visscher, MD
pathologists Rouba Ali-Fehmi, MD and Susdeshna Bandyopadhyay, MD
c145 blocks were reviewed in total. One case could not be assessed for fibroadenoma presence and
contributed to the final concordance rate, discordance rate, and Cohen’s κ
bKCI
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Women with a fibroadenoma on biopsy were more likely to be younger than women
without a fibroadenoma on biopsy (p<0.001) (Table 2). Women with fibroadenoma on biopsy
had 1.6 times higher odds of having a core-needle biopsy than excisional biopsy compared to
women without a fibroadenoma on biopsy (p<0.001). The presence of other benign breast
lesions was less likely to be indicated on biopsies containing a fibroadenoma. Women with
fibroadenoma on biopsy were 4 to 5.6 times lower odds of exhibiting cysts or intraductal
papilloma on biopsy than women without fibroadenoma on biopsy (both p<0.001). Women with
fibroadenoma on biopsy had a 3 to 4 times lower odds of exhibiting apocrine metaplasia,
fibrosis or columnar alterations on biopsy than women without fibroadenoma on biopsy (all
p<0.001). Women with fibroadenoma on biopsy had a 2 to 3 times lower odds of exhibiting
ductal hyperplasia, lobular hyperplasia, ductal ectasia, sclerosing adenosis or radial scars on
biopsy than women without fibroadenoma on biopsy (lobular hyperplasia p=0.008; all other
p<0.001). Women with fibroadenoma on biopsy were 1.67 times lower odds of exhibiting
calcifications on biopsy than women without fibroadenoma on biopsy (p<0.001). Additionally,
biopsies with a fibroadenoma were less likely to be classified as proliferative disease (25.0%) or
proliferative disease with atypia (1.3%) compared to biopsies without a fibroadenoma (51.5%
and 6.1%, respectively).
Several associations between fibroadenomas and other benign breast lesions on biopsy
remained after separating women by likely menopausal status by age (Tables 3-4). Notable
exceptions were calcifications and proliferative disease with atypia on biopsy by fibroadenoma
status. Under the age 50, women with fibroadenoma on biopsy were 3 times less likely to exhibit
calcifications on biopsy compared to women without a fibroadenoma on biopsy; in women aged
50 or older, women with fibroadenoma on biopsy were 1.26 times more likely to exhibit
calcifications on biopsy compared to women without a fibroadenoma on biopsy (95% confidence
interval 2.4 – 3.8 and 1.03 – 1.54, respectively). Under the age 50, women with fibroadenoma
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on biopsy were 20 times less likely to exhibit proliferative disease with atypia on biopsy
compared to women without a fibroadenoma on biopsy; in women aged 50 or older, women with
fibroadenoma on biopsy were 4.6 times less likely to exhibit proliferative disease with atypia on
biopsy compared to women without fibroadenoma on biopsy (95% confidence interval 9.1 – 100
and 2.8 – 7.7, respectively).
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Table 2. Distribution of benign breast features and other characteristics by fibroadenoma status
in African American women in the Detroit BBD cohort, 1997-2010
P valueb
Characteristic
Fibroadenoma status, N (%)a Odds ratio
Absent
Present
(95% CI)
2047 (53.2)
1798 (46.8)
Age at benign biopsy
<0.001
<40
387 (18.9)
573 (31.9)
Ref
40-49
692 (33.8)
582 (32.4)
0.57 (0.48 – 0.67)
50-59
577 (28.2)
374 (20.8)
0.44 (0.36 – 0.53)
60-69
249 (12.2)
164 (9.1)
0.45 (0.35 – 0.56)
70+
142 (6.9)
105 (5.8)
0.50 (0.38 – 0.66)
Biopsy Type
<0.001
Excisional
826 (40.4)
536 (30.8)
Ref
Core Needle
1221 (59.6)
1262 (70.2)
1.59 (1.39 – 1.82)
Apocrine Metaplasia
<0.001
Absent
1202 (58.7)
1401 (82.3)
Ref
Present
845 (41.3)
301 (17.7)
0.31 (0.26 – 0.36)
Ductal Hyperplasia
<0.001
Absent
1272 (62.1)
1365 (80.6)
Ref
Present
775 (37.9)
329 (19.4)
0.40 (0.34 – 0.46)
Lobular Hyperplasia
0.008
Absent
2012 (98.3)
1662 (99.3)
Ref
Present
34 (1.7)
11 (0.7)
0.40 (0.19 – 0.76)
Calcifications
<0.001
Absent
1209 (59.1)
1229 (70.8)
Ref
Present
837 (40.9)
507 (29.2)
0.60 (0.52 – 0.68)
Cysts
<0.001
Absent
970 (47.4)
1339 (78.9)
Ref
Present
1076 (52.6)
359 (21.1)
0.24 (0.21 – 0.28)
Duct Ectasia
<0.001
Absent
1652 (80.7)
1546 (91.0)
Ref
Present
394 (19.3)
152 (9.0)
0.41 (0.34 – 0.50)
Fibrosis
<0.001
Absent
648 (31.7)
1031 (63.8)
Ref
Present
1397 (68.3)
586 (36.2)
0.26 (0.23 – 0.30)
Intraductal Papilloma
<0.001
Absent
1662 (81.2)
1629 (96.1)
Ref
Present
385 (18.8)
66 (3.9)
0.18 (0.13 – 0.22)
Sclerosing Adenosis
<0.001
Absent
1416 (69.2)
1404 (82.7)
Ref
Present
630 (30.8)
294 (17.3)
0.47 (0.40 – 0.55)
Columnar Alterations
<0.001
Absent
1302 (63.6)
1439 (84.7)
Ref
Present
744 (30.8)
259 (15.3)
0.32 (0.27 – 0.37)
Radial Scar
<0.001
Absent
1975 (96.5)
1665 (98.6)
Ref
Present
71 (3.5)
23 (1.4)
0.39 (0.23 – 0.61)
Dupont and Page criteria
<0.001
Nonproliferative disease
868 (42.4)
1325 (73.7)
Ref
Proliferative disease without atypia 1054 (51.5)
450 (25.0)
0.28 (0.24 – 0.32)
Proliferative disease with atypia
125 (6.1)
23 (1.3)
0.12 (0.08 – 0.19)
Developed breast cancer
<0.001
No
1902 (92.9)
1722 (95.8)
Ref
Yes
145 (7.1)
76 (4.2)
0.58 (0.43 – 0.77)
aNumbers may not sum to the total number of patients if features could not be assessed on biopsy
b2 test comparing distribution of features across absence or presence of fibroadenoma on biopsy
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Table 3. Distribution of benign breast features and other characteristics by fibroadenoma status
for African American women under the age 50 in the Detroit BBD cohort, 1997-2010
P valueb
Characteristic
Fibroadenoma status, N (%)a
Odds ratio
Absent
Present
(95% CI)
1079 (48.3)
1155 (51.7)
Age at benign biopsy
<0.001
<40
387 (35.9)
573 (49.6)
Ref
40-49
692 (64.1)
582 (50.4)
0.57 (0.48 – 0.67)
Biopsy Type
<0.001
Excisional
450 (41.7)
371 (32.1)
Ref
Core Needle
629 (58.3)
784 (77.9)
1.51 (1.27 – 1.80)
Apocrine Metaplasia
<0.001
Absent
645 (59.8)
905 (83.7)
Ref
Present
434 (40.2)
176 (16.3)
0.29 (0.24 – 0.35)
Ductal Hyperplasia
<0.001
Absent
690 (63.9)
876 (81.5)
Ref
Present
389 (36.1)
199 (18.5)
0.40 (0.33 – 0.49)
Lobular Hyperplasia
0.072
Absent
1069 (99.2)
1065 (99.8)
Ref
Present
9 (0.8)
2 (0.2)
0.24 (0.03 – 0.94)
Calcifications
<0.001
Absent
743 (68.9)
960 (87.1)
Ref
Present
336 (31.1)
142 (12.9)
0.33 (0.26 – 0.41)
Cysts
<0.001
Absent
526 (48.7)
860 (79.9)
Ref
Present
553 (51.3)
217 (20.1)
0.24 (0.20 – 0.29)
Duct Ectasia
<0.001
Absent
853 (79.1)
977 (90.7)
Ref
Present
226 (20.9)
100 (9.3)
0.39 (0.30 – 0.50)
Fibrosis
<0.001
Absent
323 (30.0)
663 (64.9)
Ref
Present
755 (70.0)
359 (35.1)
0.23 (0.19 – 0.28)
Intraductal Papilloma
<0.001
Absent
896 (83.0)
1045 (97.1)
Ref
Present
183 (17.0)
31 (2.9)
0.15 (0.10 – 0.21)
Sclerosing Adenosis
<0.001
Absent
712 (66.0)
887 (82.4)
Ref
Present
367 (34.0)
190 (17.6)
0.42 (0.34 – 0.51)
Columnar Alterations
<0.001
Absent
705 (65.3)
931 (86.4)
Ref
Present
374 (34.7)
146 (13.6)
0.30 (0.24 – 0.37)
Radial Scar
0.003
Absent
1042 (96.6)
1061 (98.6)
Ref
Present
37 (3.4)
15 (1.4)
0.40 (0.21 – 0.72)
Dupont and Page criteria
<0.001
Nonproliferative disease
479 (44.4)
861 (74.5)
Ref
Proliferative disease without atypia 549 (50.9)
290 (25.1)
0.29 (0.25 – 0.35)
Proliferative disease with atypia
51 (4.7)
4 (0.3)
0.05 (0.01 – 0.11)
Developed breast cancer
0.021
No
1027 (95.2)
1122 (97.1)
Ref
Yes
52 (4.8)
33 (2.9)
0.58 (0.37 – 0.90)
aNumbers may not sum to the total number of patients if features could not be assessed on biopsy
b2 test comparing distribution of features across absence or presence of fibroadenoma on biopsy
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Table 4. Distribution of benign breast features and other characteristics by fibroadenoma status
for African American women aged 50 or older in the Detroit BBD cohort, 1997-2010
P valueb
Characteristic
Fibroadenoma status, N (%)a Odds ratio
Absent
Present
(95% CI)
968 (60.1)
643 (39.9)
Age at benign biopsy
0.658
50-59
577 (59.6)
374 (58.2)
Ref
60-69
249 (25.7)
164 (25.5)
1.02 (0.80 – 1.29)
70+
142 (14.7)
105 (16.3)
1.14 (0.86 – 1.51)
Biopsy Type
<0.001
Excisional
376 (38.8)
165 (25.7)
Ref
Core Needle
592 (61.2)
478 (74.3)
1.84 (1.48 – 2.29)
Apocrine Metaplasia
<0.001
Absent
557 (57.5)
496 (79.9)
Ref
Present
411 (42.5)
125 (20.1)
0.34 (0.27 – 0.43)
Ductal Hyperplasia
<0.001
Absent
582 (60.1)
489 (79.0)
Ref
Present
386 (39.9)
130 (21.0)
0.40 (0.32 – 0.51)
Lobular Hyperplasia
0.201
Absent
943 (97.4)
597 (98.5)
Ref
Present
25 (2.6)
9 (1.5)
0.58 (0.25 – 1.20)
Calcifications
0.027
Absent
466 (48.2)
269 (42.4)
Ref
Present
501 (51.8)
365 (57.6)
1.26 (1.03 – 1.54)
Cysts
<0.001
Absent
444 (45.9)
479 (77.1)
Ref
Present
523 (54.1)
142 (22.9)
0.25 (0.20 – 0.32)
Duct Ectasia
<0.001
Absent
799 (82.6)
569 (91.6)
Ref
Present
168 (17.4)
52 (8.4)
0.44 (0.31 – 0.60)
Fibrosis
<0.001
Absent
325 (33.6)
368 (61.8)
Ref
Present
642 (66.4)
227 (38.2)
0.31 (0.25 – 0.39)
Intraductal Papilloma
<0.001
Absent
766 (79.1)
584 (94.3)
Ref
Present
202 (20.9)
35 (5.7)
0.23 (0.15 – 0.33)
Sclerosing Adenosis
<0.001
Absent
704 (72.8)
517 (83.3)
Ref
Present
263 (27.2)
104 (16.7)
0.54 (0.42 – 0.69)
Columnar Alterations
<0.001
Absent
597 (61.7)
508 (81.8)
Ref
Present
370 (38.3)
113 (18.2)
0.36 (0.28 – 0.46)
Radial Scar
0.013
Absent
933 (96.5)
604 (98.7)
Ref
Present
34 (3.5)
8 (1.3)
0.37 (0.16 – 0.77)
Dupont and Page criteria
<0.001
Nonproliferative disease
389 (40.2)
464 (72.2)
Ref
Proliferative disease without atypia 505 (52.2)
160 (24.9)
0.27 (0.21 – 0.33)
Proliferative disease with atypia
74 (7.6)
19 (3.0)
0.22 (0.13 – 0.36)
Developed breast cancer
0.049
No
875 (90.4)
600 (93.3)
Ref
Yes
93 (9.6)
43 (6.7)
0.68 (0.46 – 0.98)
aNumbers may not sum to the total number of patients if features could not be assessed on biopsy
b2 test comparing distribution of features across absence or presence of fibroadenoma on biopsy
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Breast cancer risk within the BBD cohort
Adjusting for age at biopsy alone, the presence of fibroadenoma was associated with a
reduced breast cancer risk (RR 0.64; 95% CI 0.45 – 0.85) compared to the absence of
fibroadenoma within the BBD cohort (Table 5). After adjusting for age at biopsy and Dupont and
Page criteria, no other variables were selected for model selection using BIC criteria. In the fully
adjusted model including age at biopsy, proliferation, and atypia, fibroadenoma was still
associated with a reduced risk (RR 0.67; 95% CI 0.48 – 0.93) of developing breast cancer.

Table 5. Relative risk of breast cancer by fibroadenoma status in African American women in
the Detroit BBD cohort, 1997-2010
P valueb Fully-adjusted relative
P valueb
Age-adjusted relative
riska (95% confidence
risk (95% confidence
interval)
interval)
No fibroadenoma on
Ref
Ref
biopsy
Fibroadenoma
0.64 (0.48, 0.85)e
0.003
0.67 (0.48, 0.93)c,f
0.017
Fibroadenoma
No other lesions
One or more other lesions

0.63 (0.22, 2.32)g
0.67 (0.49, 0.91)i

0.435
0.013

0.59 (0.20, 2.16)c,h
0.70 (0.48, 0.99)d,j

0.367
0.047

Under age 50
No fibroadenoma on biopsy
Fibroadenoma

Ref
0.71 (0.45, 1.11)k

0.133

Ref
0.58 (0.34, 0.96)c,l

0.037

Age 50 or older
No fibroadenoma on biopsy Ref
Ref
Fibroadenoma
0.68 (0.46, 0.98)m
0.042
0.79 (0.52, 1.19)c,n
0.275
aMultivariable logistic regression model adjusting for age at biopsy
bWald test statistic
cMultivariable logistic regression models adjusting for age, proliferative disease, and cellular atypia at
biopsy
dMultivariable logistic regression adjusting for age, columnar alterations, proliferative disease, and cellular
atypia at biopsy
N at risk: e3845, f3761, g607, h607, i3238, j3000, k2234, l2071, m1611, n1536

Among biopsies without other benign breast lesions, presence of fibroadenoma was
associated with a reduced breast cancer risk when adjusting for age at biopsy though this
comparison did not reach statistical significance (RR 0.63; 95% CI 0.22 – 2.32) when compared
to absence of fibroadenoma in the Detroit BBD cohort due to limited sample size for this
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comparison. In a fully adjusted model including age at biopsy, proliferation and atypia,
fibroadenoma was still associated with reduced breast cancer risk but not significantly so (RR
0.59; 95% CI 0.20 – 2.16). Among biopsies containing one or more other benign breast lesions,
presence of fibroadenoma was associated with a reduced breast cancer risk when adjusting for
age at biopsy when compared to the absence of fibroadenoma on biopsy in the Detroit BBD cohort
(RR 0.67; 95% CI 0.49 – 0.91). In a fully adjusted model controlling for age at biopsy, columnar
alterations, epithelial proliferation and cellular atypia on biopsy, fibroadenoma was still associated
with a reduced breast cancer risk (RR 0.70; 95% CI 0.48 – 0.99).
Fibroadenoma diagnosed in women under the age of 50 was associated with a decrease
in breast cancer risk after adjusting for age at biopsy, but not significantly so (RR 0.71; 95% CI
0.45 – 1.11). After additionally adjusting for proliferation and cellular atypia, fibroadenoma on
biopsy was associated with a significant decrease in breast cancer risk in women under the age
of 50 (RR 0.58; 95% CI 0.34 – 0.96). Fibroadenoma diagnosed in women aged 50 or older also
show a reduction in breast cancer risk when adjusting for age at biopsy (RR 0.68; 95% CI 0.46 –
0.98); however, this reduction failed to reach statistical significance, likely due to limited sample
size, after adjusting for age at biopsy, proliferation and cellular atypia (RR 0.79; 95% CI 0.52 –
1.19).
Breast cancer risk compared to population level risk
Overall, this cohort of women exhibited an increased incidence of approximately 20% (SIR
1.19; 95% CI 1.05 – 1.36) of breast cancer compared to the general African American population
in Metropolitan Detroit (Table 6). Stratifying the cohort by presence of fibroadenoma on biopsy
revealed that breast cancer incidence associated with fibroadenoma was indistinguishable from
population level (SIR 0.93; 95% CI 0.75 – 1.17), but the breast cancer incidence associated with
the absence of fibroadenoma on biopsy was significantly higher than population level (SIR 1.40;
95% CI 1.19 – 1.65).
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Table 6. Risk of breast cancer in African American women in the Detroit BBD cohort compared
to population level breast cancer risk in African American women in the Metropolitan Detroit
Cancer Surveillance System between 1997 and 2015
Total no
Observed
Expected
SIRa (95% CI)
cases
cases
Population rate
N/A
N/A
N/A
Ref
Entire BBD cohort
3845
221
185.02
1.19 (1.05 – 1.36)
Biopsy without fibroadenoma
Fibroadenoma

2047
1798

145
76

103.56
81.46

1.40 (1.19 – 1.65)
0.93 (0.75 – 1.17)

Biopsies without fibroadenoma
Nonproliferative disease
Proliferative disease
Proliferative disease with atypia

868
1054
125

47
81
17

44.42
52.45
6.69

1.06 (0.80 – 1.40)
1.54 (1.24 – 1.92)
2.54 (1.58 – 4.09)

Biopsies with fibroadenoma
Nonproliferative disease
Proliferative disease
Proliferative disease with atypia

1325
450
23

55
16
5

59.52
20.73
1.21

0.92 (0.71 – 1.20)
0.77 (0.47 – 1.26)
4.14 (1.72 – 9.94)

No other lesions
546
17
22.62
0.75 (0.47 – 1.21)
One or more other lesions
1252
59
58.84
1.00 (0.78 – 1.29)
aStandardized incidence ratio (SIR) compares the observed number of breast cancers that developed in
the study to the number expected on the basis of the Detroit surveillance, epidemiology, and end results
data for African American women of a similar age and calendar period

In biopsies that did not indicate fibroadenoma presence, stratifying by Dupont and Page
criteria showed that compared to population level breast cancer incidence: nonproliferative
disease was associated with slight but not significantly increased incidence (SIR 1.06; 95% CI
0.80 – 1.40), proliferative disease was associated with an increased incidence (SIR 1.54; 95% CI
1.24 – 1.92), and proliferative disease with atypia was associated with an increased incidence
(SIR 2.54; 95% CI 1.58 – 4.09).
In biopsies that indicated fibroadenoma presence, stratifying by Dupont and Page criteria
showed that compared to population level breast cancer incidence: nonproliferative disease was
associated with slight but not significantly decreased incidence (SIR 0.92; 95% CI 0.71 – 1.20),
proliferative disease was also associated with a slight but not significantly decreased incidence
(SIR 0.77; 95% CI 0.47 – 1.26), and proliferative disease with atypia was associated with an
increased incidence (SIR 4.14; 95% CI 1.72 – 9.94). In biopsies that indicated fibroadenoma
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presence, stratifying by the presence of one or more benign breast biopsy showed that compared
to population level breast cancer incidence: no other breast lesions was associated with a
reduced, but not significantly so, incidence (SIR 0.75; 95% CI 0.47 – 1.21); one or more other
benign breast lesions was not associated with a different incidence (SIR 1.00; 95% CI 0.78 –
1.29).
Cumulative incidence of cancers in subgroups
Women with fibroadenoma on biopsy accumulated fewer breast cancers over the study
period than women without fibroadenoma on biopsy (Figure 2; Fine and Gray test p<0.001).
Stratifying by likely menopausal status by age indicated the incidence of breast cancers was lower
in women under the age of 50 than in women aged 50 or older (Figure 3). In both strata, women
with fibroadenoma on biopsy accumulated fewer cancers over the study period than women
without fibroadenoma on biopsy (Fine and Gray test p=0.014 for under age 50; p=0.059 for age
50 and older).
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Fig. 2 Cumulative incidence of in situ and invasive breast carcinomas over study period in African
American women in the Detroit BBD cohort, 1997-2010. Women with biopsies that indicated
fibroadenomas accumulated fewer breast cancers over the study period than women whose biopsies did
not indicate fibroadenomas. Fine and Gray test p<0.001
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Fig. 3 Cumulative incidence of in situ and invasive breast carcinomas over study period by likely
menopausal status by age in African American women in the Detroit BBD cohort, 1997-2010. (A)
Women under the age of 50 with biopsies indicating fibroadenomas accumulated fewer breast cancers
over the study period than women under the age of 50 whose biopsies did not indicate fibroadenomas.
Fine and Gray test p=0.014. (B) Women aged 50 or older with biopsies indicating fibroadenomas
accumulated fewer breast cancers over the study period than women aged 50 or older whose biopsies
did not indicate a fibroadenoma. Fine and Gray test =0.059

IV. Discussion
Here we report findings from a contemporary cohort of African American women who have
had a breast biopsy that show that biopsies that indicated a fibroadenoma were associated with
a reduced risk of breast cancer compared to biopsies with other BBD lesions even after adjusting
for age, proliferative disease and atypia. Additionally, we found that women with a fibroadenoma
observed on biopsy were not at increased risk of subsequent breast cancer compared to the
general population of African American women. These findings suggest that current breast cancer
risk models that incorporate benign biopsies without considering the pathological lesion
overestimate risk in African American women who have fibroadenomas on biopsy. Given that
fibroadenomas were identified in nearly half of all breast biopsies in this population, and were the
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only lesion identified in 19% of all biopsies, these findings represent a significant clinical
population. In comparison, fibroadenomas were identified in only 23.5% of the biopsies of the
primarily European American Mayo Clinic cohort59.
Our investigation suggests that biopsies indicating fibroadenoma exhibit a reduced risk of
breast cancer compared to all other BBD biopsies, contrary to most other studies’ estimates of
increased risk of breast cancer56. Discordant risk estimates between our investigation and those
from other studies may reflect differences in race, age, and period of cohorts utilized. The
Nashville group60, which found a significant increase in breast cancer risk with fibroadenoma (SIR
1.61; 95% CI 1.30 – 2.00) compared to the Connecticut Tumor Registry, studied European
American women diagnosed with a fibroadenoma between 1950 and 1968. The Mayo Clinic
benign breast disease (BBD) cohort59 studied European American women diagnosed with
fibroadenoma between 1967 and 1991 and found modest increases breast cancer risk with
fibroadenoma (SIR 1.60; 95% CI 1.38 – 1.85) compared to biopsies without fibroadenoma (SIR
1.50; 95% CI 1.39 – 1.62). A BBD cohort from Henry Ford Health System (HFHS), where women
with fibroadenomas on biopsy had a decreased odds (OR 0.55; 95% CI 0.39 – 0.77) of developing
breast cancer compared to women without fibroadenoma on biopsy, more closely approximates
our risk estimates42. Worsham et al42 studied a mixed cohort of European American and African
American women in metropolitan Detroit diagnosed between 1981 and 1994. However, it is
unlikely that the differences in risk estimates are due solely to race: the HFHS group tested an
interaction factor between race and BBD and did not find statistical significance42.
Period effects may also contribute to variation in risk estimates. Inclusion criteria for BBD
studies span from 1950 to 2010; thus, differences in risk estimates may also reflect the
endogenous and exogenous exposures that varied over this period. Exogenous hormone use,
including hormone replacement therapy and contraceptive use have changed in frequency, dose,
and formulation. Changes in exogenous hormone use can alter total estrogen exposure, a strong
breast cancer risk factor, and influence risk estimates of tissue-based markers61,62. Environmental
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exposures that vary over time and/or geographic areas can further add to risk estimate variation.
Changes in the indication for biopsy is perhaps the most pertinent shift over these study periods:
physicians are more likely to biopsy now than in the 1950s. Population uptake of mammography
began in the 1970s63 and screening technology has continued to improve since64,65, leading to an
increase in breast biopsy incidence. The adoption of core needle biopsies, which are less invasive
than excisional biopsies, further increased the likelihood of a breast biopsy, especially in what are
considered high-risk populations.
The strengths of our study stem from the cohort study design where all breast biopsies
were re-examined for benign lesions in a centralized and standardized manner by WSU
pathologists, and identification of breast cancers occurred through institution medical records and
then standardized for the region through use of the population-based SEER registry. This allowed
for the identification of breast cancers among women who sought care outside of the hospitals
served by the University Pathology Group.

In addition, linkage to MDCSS allowed for

identification of other causes of death, so that competing risk analyses could be performed.
It should be noted there are limitations to our study. First, the population estimates used
in the SIR analysis includes women who have been diagnosed with benign breast disease in the
metropolitan Detroit area, thus the SIR may slightly underestimate the risk associated with breast
cancer. We are also limited by the passive follow-up for in situ and invasive breast carcinoma
incidence in this study; women who move out of metropolitan Detroit would be missed, also
underestimating breast cancer risk in this study. Next, our assessment was limited to the presence
or absence of fibroadenomas on breast biopsy, but there may be added value in assessing
whether these fibroadenomas exhibit other BBD lesions, data that were not collected in the
original study design. There are conflicting reports on the breast cancer risk associated with
complex fibroadenomas, or fibroadenomas that contain cysts, calcifications, sclerosing adenosis,
and/or apocrine metaplasia59,60. Because of the high prevalence of fibroadenomas in this
population, breast cancer risk associated with complex fibroadenoma should also be
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independently reviewed in African American women. We are also limited by behavioral risk factor
information we were unable to collect or unable to measure in the original study design that may
confound these risk estimates.
Currently, a diagnosis of fibroadenoma requires no further intervention, and is followed by
a primary care physician or gynecologist unless the patient elects to have to mass removed,
usually due to size of the tumor, recurrence, or pain66,67. As previous investigations of
fibroadenoma on biopsy estimated an elevated risk of breast cancer that persists for 20 years60,
physicians may currently screen women with fibroadenomas frequently. Our study suggests that
fibroadenomas do not increase risk of subsequent breast cancers. Ultimately, examining specific
features of BBD will improve risk estimates used in breast cancer risk models, reduce patient
anxiety, and improve management of fibroadenoma in the clinic by reducing overscreening and
overtreatment of this population, both associated with potential patient harms and excessive
resource allocation.
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CHAPTER 3: BREAST DENSITY AND PARENCHYMAL PATTERNS IN AFRICAN
AMERICAN WOMEN
I. Introduction
Breast density, whether measured qualitatively or quantitatively, has been consistently
associated with increased breast cancer risk44,68. Mammograms exhibiting more than 75% density
are associated with about a four-fold increase in breast cancer risk compared to those in the least
dense category of under 25% density44,68. High breast density is thought to increase breast cancer
risk as it equates to increased connective and epithelial tissue, tissues highly associated with
breast carcinogenesis. Increased breast density may also mask small growths on film, leading to
delayed cancer detection, but not the primary mechanism by which breast density contributes to
breast cancer risk.
Despite the increased rate of aggressive breast cancer incidence and breast cancer
mortality in African American women compared to European American women2,9,10, few studies
have assessed breast density and subsequent risk of breast cancer in African American women.
Tice et al.49 included over 2800 African American women from the multi-center Breast Cancer
Screening Consortium, but this analysis only adjusted for race and did not report race-specific
estimates. Race-specific estimates are necessary as African American women present differently
in BBD53, breast density50,51,69, and breast cancer subtype9,12. After adjusting for age and BMI,
African American women are more likely to have dense breasts than European American women
on quantitative density measures51.
Recent analyses showed that qualitative assessments by radiologists were similar, if not
better, than quantitative assessments of breast density at discriminating between future breast
cancer cases and controls70,71. This work suggests that there are features other than density on
mammogram associated with breast cancer that radiologists are able to detect but are missed by
automated measures. Other radiologic classification methods including the Tabár classification72,
which describes the appearance of the breast tissue or parenchyma on mammogram, are not

29
routinely used as breast density has been more strongly linked to breast cancer, but this
classification may have renewed potential as contrast resolution and image quality have greatly
improved with the switch from film to digital mammography73. High-risk Tabár patterns include
nodular or extremely dense breasts, which are at 2.5 times higher odds of developing breast
cancer than other, low-risk patterns74. Qualitative density and parenchymal patterns of the breast
may be particularly important for women with benign breast disease (BBD), a higher-risk
population which may deserve additional surveillance and assessment on mammogram. Here we
sought to investigate the association between qualitative density and parenchymal patterns with
breast cancer in African American women with BBD.
II. Methods
Study design
Here we conducted a case/control study nested within the Detroit BBD cohort to
examine whether qualitative breast density and parenchymal patterns are associated with
breast cancer in African American women with BBD. Our main outcome of interest was the
presence or absence of in situ or invasive breast carcinoma. The main exposures of interest
include the BI-RADS density score, Tabár classification, and a complexity indicator score
created by our study radiologists.
We also examined whether the association between BI-RADS density and breast cancer
differed among women with BBD or the population by additionally examining this association in
African American women undergoing routine screening in Detroit over a similar time period
using the Detroit Screening cohort. Utilizing this cohort allows us to evaluate potential
differences that may stem from race, period, or site differences that may limit our direct
comparisons to other studies.
Study populations
Study participants included all breast cancer cases (n=214) and controls (n=214) matched
on five-year age groups and year at biopsy from the Detroit BBD cohort. The Detroit BBD cohort
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comprises African American women diagnosed with BBD between 1997 and 2010 and followed
for breast cancer current through December 2015; additional study details can be found in
Chapter 2. For this study, cases and controls were eligible if a screening or diagnostic
mammogram within five years of the BBD diagnosis and before the in situ or invasive breast
carcinoma diagnosis was available for review in film or digital format. Mammographic films were
digitized for review. This study protocol was approved by the Institutional Review Board of Wayne
State University. Individual consent was not required as this study was retrospective in design
and carried minimal risk to participants.
To examine breast density differences between women with or without BBD, the Detroit
BBD cohort was compared to the Detroit Screening cohort. The Detroit Screening cohort is a
retrospective cohort of all European American and African American women who underwent
routine mammographic screening at Karmanos Cancer Institute (KCI) from January 1, 2012 to
December 31, 2016. Patients were identified from the KCI Image Department database where
medical record numbers, date of birth, mammogram type and date, age and race were available.
Women with a prior history of breast cancer or a breast cancer within six months of the initial
mammogram were excluded. Breast cancer diagnosis and vital status were ascertained using
MDCSS linkage.
Mammographic breast features
Screening or diagnostic mammograms from the Detroit BBD cohort were independently
assessed by breast radiologists at KCI blinded to case/control status. Study radiologists reviewed
mammographic density and parenchymal patterns on mediolateral-oblique and cranio-caudal
views together and a final density or pattern score were given after the radiologists came to a
consensus. If density or pattern scores were discordant between right and left breasts, the most
suspicious score was utilized for analysis. If only one breast was available for viewing, the density
or pattern score for this breast was utilized for analysis. Only one density or parenchymal pattern
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was scored for mammographic images at a time; sessions focused on reading one parameter to
increase speed (by not switching measures).
Breast density was evaluated qualitatively using the American College of Radiology (ACR)
Breast Imaging Reporting and Data System (BI-RADS) density score75. This density score
classifies breast tissue into four categories by the amount of fatty and radiolucent tissue to
fibroglandular and radio-opaque tissue seen on film including: (A) predominantly fat, (B) scattered
fibroglandular densities, (C) heterogeneously dense, and (D) extremely dense tissue. BI-RADS
density for the Detroit screening cohort was abstracted from PACS imaging reports.
Study radiologists also categorized mammograms by the Tabár classification of
parenchymal patterns72,74. This classification sorts mammograms into five patterns based on four
features with anatomic significance: radiolucent areas (adipose), linear densities (ducts), nodular
densities (terminal duct lobule units (TDLU)), and homogenous densities that lack structure
(fibrosis). Patterns include: (I) breasts that include all four features equally represented, scalloped
contours, and oval fatty areas. (II) Predominately fatty tissue with linear densities. (III)
Predominately fatty but with significant densities, often linear (prominent ductal pattern), in the
retroareolar region. (IV) Predominately enlarged nodular densities and linear densities (indicating
proliferating TDLUs and periductal fibrosis). (V) Predominately homogenous density with groundglass-like appearance.
Mammographic images were also scored for a novel complexity indicator described by
our study radiologists. This indicator reflected the complexity and suspicion raised (categorized
as uncomplicated, borderline and complicated) for all study mammograms. Complexity for an
image increased with the presence of multiple interfaces or changes in breast tissue density,
which would necessitate additional time to sufficiently review. Areas of density that were patchy,
nodular or diffuse on mammogram raised suspicion that a developing tumor may be missed and
contributed to this complexity indicator. For each image, study radiologists made an overall call
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(uncomplicated, borderline, or complicated) followed by the components that contributed to the
overall call (multiple interfaces as well as patchy, nodular, or diffuse areas of density).
C. Statistical approaches
Our first objective was to examine the distribution of clinicopathologic characteristics
among the cases and controls in the final study population from the Detroit BBD cohort.
Clinicopathologic characteristics were described in percentages and included age, likely
menopausal status by age (pre-, peri-, and postmenopausal), year of biopsy, mammogram type,
biopsy type, Dupont and Page criteria for epithelial proliferation and cellular atypia on biopsy, vital
status. We evaluated potential differences in clinicopathologic characteristics among cases and
controls using Pearson chi-square tests. Differences in mean age was tested using a one-way
ANOVA. Median time to cancer diagnosis was determined by a Kaplan Meier estimator; median
time of follow-up for controls was determined by the reverse Kaplan Meier method.
Our second objective was to examine whether mammographic density and parenchymal
patterns were associated with breast cancer in African American women with BBD. We described
the distribution of mammograms in the nested study from the Detroit BBD cohort by BI-RADS
density, Tabár classification, and complexity indicator status using percentages. We evaluated
the odds of having breast cancer by density or parenchymal pattern status with conditional logistic
regression adjusting for epithelial proliferation and cellular atypia on biopsy (likely confounders
for BBD studies Dupont 1985) and stratifying for 5-year age and biopsy groups. Although BMI is
an important variable to adjust for in this analysis, we were unable to ascertain the BMI for all
women in the final study population from the Detroit BBD cohort.
Our third objective was to examine the association between mammographic density and
breast cancer in the larger population of African American women in Detroit undergoing routine
screening. We evaluated this association by estimating the odds of having breast cancer in the
Detroit Screening Cohort by BI-RADS density using logistic regression adjusting for age and BMI.
III. Results
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Clinicopathologic characteristics
The final nested case/control study from the Detroit cohort consisted of 126 cases and
151 controls. The mean age of the study population was 53.6 years and did not differ between
cases and controls (p=0.358). Likely menopausal status by age was 36.8% premenopausal and
63.2% postmenopausal; likely menopausal status did not differ by cases and controls (Table 7,
p-value=1). Year of biopsy did not differ between cases and controls (p=0.823); 33.9% of biopsies
were conducted between 1997-2000, 40.0% between 2001-2005, and 26.0% between 20062010. The majority of images assessed were screening mammograms (53.4%); mammogram
type did not differ between cases and controls (p=1). Indication for an excisional biopsy may
indicate a larger area of suspicious tissue; however, the majority of biopsies were core-needle
(63.9%) and did not significantly differ by case status (p=0.079). Cases showed a larger proportion
of proliferative disease with atypia (PDWA) than controls (11.1% versus 4.0%; p=0.044). 16.6%
of the study population is deceased, and this proportion did not significantly differ among cases
and controls (p=0.4036).
Table 7. Distribution of clinicopathologic characteristics among African American women in a
case/control study nested in the Detroit BBD cohort, 1997-2010
Controls (N=151)
Cases (N=126)
p-valuea
Age
1
Premenopausal (< 50)
56 (37.1%)
46 (36.5%)
Premenopausal (≥ 50)
95 (62.9%)
80 (63.5%)
Year of biopsy
0.8233
1997-2000
52 (34.4%)
42 (33.3%)
2001-2005
62 (41.1%)
49 (38.9%)
2006-2010
37 (24.5%)
35 (27.8%)
Mammogram type
1
Screening
81 (53.6%)
67 (53.2%)
Diagnostic
70 (46.4%)
59 (46.8%)
Biopsy type
0.0792
Excisional
62 (41.1%)
38 (30.2%)
Core Needle
89 (58.9%)
88 (69.8%)
0.0440
Histological impression
Non-proliferative disease
71 (47.0%)
62 (49.2%)
Proliferative disease
74 (49.0%)
50 (39.7%)
Proliferative disease with atypia
6 (4.0%)
14 (11.1%)
Vital Status
0.4036
Alive
129 (85.4%)
102 (81.0%)
Deceased
22 (14.6%)
24 (19.0%)
aPearson chi-square tests
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Median time to cancer diagnosis in cases was 6.3 years (range 0.7 – 17.2 years).
Median time of follow up for controls was 12.6 years (range 3.0 – 18.9 years). Median time
between biopsy and mammogram date was 0.10 years for controls (range 4.96 years prior to
4.16 years post biopsy) and 0.13 years for cases (range 4.7 years prior and 2.16 years post
biopsy).
Density and parenchymal patterns
Table 8 summarizes the distribution of ACR BI-RADS density scores, Tabár
classifications, and Complexity categories across cases and controls from the Detroit BBD cohort.
79% of mammograms were considered density categories B (scattered densities) and C
(heterogeneously dense) regardless of case/control status. The odds of having breast cancer
were elevated and increased with density categories B, C, and D (extremely dense) compared to
the odds of having breast cancer in fatty breasts (BI-RADS category A), consistent with prior
findings from other studies (OR 1.83, 1.70, 2.69, respectively), but these estimates did not reach
statistical significance. The odds of having breast cancer with dense breasts (categories C & D)
were elevated but not significant compared to non-dense breasts (categories A & B; OR 1.15,
95% CI 0.69 – 1.90). Associations with BI-RADs categories did not reach statistical significance,
likely due to sample size limitations. With 80% power, we are able to detect a minimum odds ratio
for dense breasts (category C & D) of 2.05.
The majority of controls were considered Tabár patterns II (32.7%) and I (28.7%); the
majority of cases were considered Tabár patterns I (29.6%) and IV (26.4%). Compared to
mammograms classified as Tabár pattern II or primarily fatty replacement, mammograms with a
Tabár pattern IV or primarily nodular densities conferred a 2.83 times higher odds of breast cancer
(95% CI: 1.35-5.91). Mammograms with Tabár patterns I, III and V conferred very modestly
increased odds of having breast cancer compared to Tabár pattern I, but not significantly so
(p=0.309, 0.434, and 0.701, respectively).
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The majority of controls had mammograms categorized as uncomplicated (45.0%); the
majority of cases were categorized as complicated (46.8%). About 20% of mammograms from
cases and controls were categorized as borderline. A complicated mammogram conferred an
approximate 2-fold increase in breast cancer risk (OR 1.92, 95% CI: 1.07-3.43) compared to
uncomplicated mammograms. A borderline mammogram conferred an odds increase in breast
cancer by 1.16 (OR 1.16, 95% CI: 0.58 – 2.29); though not statistically significant, this association
indicates an increasing trend in breast cancer risk similar to the qualitative density categories.

Table 8. Distribution of parenchymal density or patterns on mammogram and associations with
breast cancer among African American women in a case/control study nested in the Detroit BBD
cohort, 1997-2010
Parenchymal pattern
Controls
Cases
Odds ratio (95% CI)
p-valuea
(N=151)
(N=126)
ACR BI-RADS
A. Fatty
24 (15.9%)
12 (9.5%)
Ref
-B. Scattered densities
56 (37.1%)
52 (41.3%)
1.83 (0.81 – 4.14)
0.146
C. Heterogeneously dense 61 (40.4%)
50 (39.7%)
1.70 (0.74 – 3.89)
0.210
D. Extremely dense
10 (6.6%)
12 (9.5%)
2.69 (0.85 – 8.51)
0.091
Non-dense (A & B)
Dense (C & D)
Tabár classification
I. Equal
II. Fatty
III. Retroareolar
IV. Nodular
V. Dense
Missing

80 (53.0%)
71 (47.0%)

64 (50.8%)
62 (49.2%)

Ref
1.15 (0.69 – 1.90)

-0.083

43 (28.7%)
49 (32.7%)
10 (6.7%)
20 (13.3%)
28 (18.7%)
1

37 (29.6%)
28 (22.4%)
10 (8.0%)
33 (26.4%)
17 (13.6%)
1

1.42 (0.73 – 2.75)
Ref
1.52 (0.53 – 4.31)
2.83 (1.35 – 5.91)
1.18 (0.50 – 2.78)

0.309
-0.434
0.006
0.701

Complexity indicator
Uncomplicated
68 (45.0%)
44 (34.9%)
Ref
Borderline
31 (20.5%)
23 (18.3%)
1.16 (0.58-2.29)
Complicated
52 (34.4%)
59 (46.8%)
1.92 (1.07-3.43)
aP-value from conditional logistic regression adjusting for histologic impression

-0.678
0.028

Table 9 shows the distribution of all mammograms by the four BI-RADS density and the
five Tabár classification categories. There is some overlap between patterns, but no categories
or patterns completely overlap. All images considered BI-RADS density A or fatty breasts were
categorized as the predominantly fatty Tabár II pattern; in contrast, images considered Tabár II
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pattern were categorized as either BI-RADS A (46.8%) or BI-RADS B (53.2%). Images considered
BI-RADS density B or scattered densities were categorized as Tabár patterns I (37.4%), II
(38.3%), III (13.0%), and IV (11.2%). Images considered BI-RADS density C or heterogeneously
dense were categorized as Tabár patterns I (36.4%), III (5.5%), IV (33.6%), and V (24.5%).
Images considered BI-RADS density D or extremely dense were categorized as either Tabár
pattern IV (18.2%) or V (81.8%). Images considered Tabár pattern I or the equal pattern were
categorized as either BI-RADS density B (50%) or C (50%). Images considered Tabár pattern III
or primarily retroareolar densities were categorized as either BI-RADS density B (70%) or C
(30%). Images considered Tabár pattern IV or primarily nodular densities were categorized as BIRADS density B (22.6%), C (69.8%), or D (7.5%). Images considered Tabár pattern V or diffusely
dense were categorized as either BI-RADS density C (60%) or D (40%).

Table 9. Distribution of ACR BI-RADS density by Tabár classification categories among African
American women in a case/control study nested in the Detroit BBD cohort, 1997-2010
Parenchymal pattern ACR BI-RADS density
A. Fatty
B. Scattered
C. Heterogeneously D. Extremely
densities
dense
dense
Tabár classification
I. Equal
0
40
40
0
II. Fatty
36
41
0
0
III. Retroareolar
0
14
6
0
IV. Nodular
0
12
37
4
V. Dense
0
0
27
18

Table 10 shows the distribution of all mammograms by the four BI-RADS density and the
three complexity indicator categories. Similar to Table 9, there is some overlap between
categories, but no categories completely overlap. All images considered BI-RADS density A or
fatty breasts were categorized as the uncomplicated pattern. All images considered BI-RADS
density B or scattered densities were categorized into all three complexity indicator categories
uncomplicated, borderline, and complicated (66.7%, 25.9%, and 7.4%, respectively). All images
considered BI-RADS density C or heterogeneously dense were categorized into all three
complexity indicator categories uncomplicated, borderline, and complicated (3.6%, 21.6%, and
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74.8%, respectively). All images considered BI-RADS density D or extremely dense were
categorized as either borderline or complicated (9.1% and 90.1%). All images considered
uncomplicated by the complexity indicator were categorized into BI-RADS densities A (32.1%), B
(64.3%), or C (3.6%). All images considered borderline were categorized into BI-RADS densities
B (51.9%), C (44.4%), or D (3.7%). All images considered complicated were categorized into BIRADS densities B (7.2%), C (74.8%), or D (18.0%).

Table 10. Distribution of ACR BI-RADS density by Complexity indicator categories among African
American women in a case/control study nested in the Detroit BBD cohort, 1997-2010
Parenchymal pattern ACR BI-RADS density
A. Fatty
B. Scattered
C. Heterogeneously D. Extremely
densities
dense
dense
Complexity indicator
Uncomplicated
36
72
4
0
Borderline
0
28
24
2
Complicated
0
8
83
20

Table 11 shows the distribution of all mammograms by the three complexity indicator
and five Tabár pattern categories. Images classified as uncomplicated were categorized as
Tabár classification I (20.5%), II (65.2%), III (9.8%), and IV (4.5%). Images classified as
borderline were categorized as Tabár classification I (58.5%), II (5.7%), III (15.1%), IV (11.3%),
and V (9.4%). Images classified as complicated were categorized as Tabár classification I
(23.6%), II (0.9%), III (0.9%), IV (38.2%), and V (36.4%). Images classified as Tabár
classification I were categorized as uncomplicated (28.8%), borderline (38.8%), and
complicated (32.5%). Images classified as Tabár classification II or primarily fatty were
categorized as uncomplicated (94.8%), borderline (3.9%), and complicated (1.3%). Images
classified as Tabár classification III or primarily retroareolar densities were categorized as
uncomplicated (55%), borderline (40%), and complicated (5%). Images classified as Tabár
classification IV or nodular densities were categorized as uncomplicated (9.4%), borderline
(11.3%), and complicated (79.2%). Images classified as Tabár classification V or diffusely
dense were categorized as either borderline (11.1%) or complicated (88.9%).

38
Table 11. Distribution of Complexity indicator by Tabár classification categories among African
American women in a case/control study nested in the Detroit BBD cohort, 1997-2010
Parenchymal pattern Complexity indicator
Uncomplicated
Borderline
Complicated
Tabár classification
I. Equal
23
31
26
II. Fatty
73
3
1
III. Retroareolar
11
8
1
IV. Nodular
5
6
42
V. Dense
0
5
40

Complicated mammograms
The characteristics on mammogram that contribute to the complexity and raised suspicion
are summarized in Table 12. Virtually all mammograms considered borderline or complicated
show multiple interfaces of density changes within the breast parenchyma; only 35.7% of
mammograms considered uncomplicated show these interfaces. The proportion of features that
raise suspicion, including patchy areas of densities, nodular densities or general diffuse density
on mammogram, also show clear increases with complexity indicator categories.
Table 12. Distribution of parenchymal characteristics contributing to the Complexity indicator
score among African American women in a case/control study nested in the Detroit BBD cohort,
1997-2010
Overall
Uncomplicated Borderline
Complicated
(N=277)
(N=112)
(N=54)
(N=111)
Multiple interfaces
40 (35.7%)
53 (98.1%)
107 (96.4%)
Patchy
3 (2.7%)
34 (63.0%)
87 (78.4%)
Nodular
6 (5.4%)
18 (33.3%)
51 (45.9%)
Dense
3 (2.7%)
35 (64.8%)
105 (94.6%)

Table 13 summarizes the distribution of characteristics that contribute to complexity
indicator among cases and controls. Multiple interfaces, patchy areas, and diffusely dense areas
were similarly distributed among cases and controls. Nodular densities were seen more frequently
in cases than controls (35.6% versus 19.9%) and the presence of this feature was associated
with a 2.33 higher odds of having breast cancer (95% CI: 1.33 – 4.09, p-value=0.003) compared
to the absence of this feature on mammogram. After adjusting for Dupont and Page criteria and
the presence of all of the complexity indicator characteristics, nodular densities on mammogram
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is associated with a 2.47 higher odds of having breast cancer (95% CI; 1.34 – 4.56, pvalue=0.004), suggesting that the nodular densities drives the statistically significant association
between breast cancer and the complexity indicator.
In this study, 36 mammograms were considered both pattern IV on Tabár and nodular by
the complexity indicator; this correlates to 68% of all mammograms considered pattern IV and
49% of all mammograms considered Tabár. As breast cancer risk factors, pattern IV on Tabár
shows higher specificity than the nodular characteristic on our complexity indicator (86.7% versus
80.1%), but lower sensitivity (26.4% versus 35.6%).

Table 13. Distribution of parenchymal characteristics contributing to the Complexity indicator
score associations with breast cancer among African American women in a case/control study
nested in the Detroit BBD cohort, 1997-2010
Controls
Cases
Odds ratioa
p-valuea Odds ratiob
p-valueb
(N=151)
(N=126)
(95% CI)
(95% CI)
Multiple interfaces 106 (70.2%) 94 (74.6%) 1.30
0.368
1.01
0.970
(0.74 – 2.29)
(0.49 – 2.08)
Patchy
62 (41.1%)
62 (49.2%) 1.49
0.142
1.83
0.095
(0.88 – 2.52)
(0.90 – 3.73)
0.003
0.004
Nodular
30 (19.9%)
45 (35.6%) 2.33
2.47
(1.33 – 4.09)
(1.34 – 4.56)
Dense
77 (51.0%)
66 (52.4%) 1.05
0.847
0.57
0.1360
(0.64 – 1.73)
(0.27 – 1.19)
aConditional logistic regression adjusting for histologic impression
bConditional logistic regression adjusting for histologic impression and all other complexity indicator
characteristics.

Density for women in Detroit
To compare effect estimates for the association between density categories and breast
cancer between women with BBD versus the routine screening population, we also examined this
association in the Detroit Screening Cohort. The distribution of ACR BI-RADs density scores
among African American women in the Detroit Screening Cohort is summarized in Table 14. The
majority (81.5%) of control mammograms were classified as BI-RADS density A fatty or B
scattered densities. The majority (81.8%) of case mammograms were classified as BI-RADS
density B scattered densities or C heterogeneously dense. Compared to mammograms showing
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a BI-RADs density A or fatty pattern, mammograms with density B, C, and D all conferred
significantly increased odds of breast cancer compared to BI-RADS density A or fatty breasts (OR
2.59, 5.05, and 2.89, respectively). Though the estimates from the Detroit Screening Cohort
differed slightly from estimates from the Detroit BBD Cohort, the 95% confidence intervals for the
odds ratios for each BI-RADS density category overlapped between cohorts (Table 8 and 14).
This suggests that the differences in odds ratio estimates may stem from the limited sample size
or lack of BMI adjustment of the nested case/control study from the Detroit BBD Cohort rather
than a biological difference in the associations between density and breast cancer in women with
or without BBD.

Table 14. Distribution of ACR BI-RADs density and associations with breast cancer among African
American women in the Detroit Screening Cohort, 2012-2016
Controls
Cases
Odds ratio (95% CI)
p-valuea
(N=14314)
(N=275)
A. Fatty
4384 (30.6%)
45 (16.4%)
Ref
-<0.001
B. Scattered densities
7287 (50.9%)
154 (56.0%)
2.59 (1.85 – 3.70)
<0.001
C. Heterogeneously dense 2318 (16.2%)
71 (25.8%)
5.05 (3.35 – 7.66)
0.029
D. Extremely dense
325 (2.3%)
5 (1.8%)
2.89 (0.98 – 6.86)
aP-value from logistic regression adjusting for Age and BMI

IV. Discussion
Here we report findings from a case/control study nested in a contemporary cohort of
African American women with BBD examining qualitative breast density and parenchymal
patterns and their associations with breast cancer. Although ACR BI-RADS was not a significant
risk factor in this study, we found similar effect estimates for this categorical variable and breast
cancer found in prior studies; with a limited sample size we did not have the power needed for
statistical significance. We found statistically significant OR estimates from using the Tabár
classification and our described Complexity indicator. The strength of these risk factors is strongly
driven by nodular patterns on breast parenchyma. This evidence suggests that among women
with BBD, parenchymal patterns may be a strong predictor of subsequent breast cancer risk.
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Other studies of the Tabár classification have indicated that patterns IV and V are “high
risk” while patterns I, II, and III are low risk72,74. In our study we were only able to recapitulate the
finding that pattern IV was associated with breast cancer72,74,76; we found a smaller proportion of
pattern V in our cases than controls (13.6% versus 18.7%). Our complexity indicator showed
significant overlap with the Tabár classification, particularly for the nodular densities on breast
parenchyma. One key difference between our complexity indicator and the Tabár classification is
that our indicator does not require a reviewer to choose a predominating parenchymal pattern. If
several features exist on mammogram, these will be preserved by the complexity indicator but
may be lost in the Tabár classification.
Our study suggests that African American women with BBD exhibit denser breasts on
mammography than the wider metro-Detroit population: 48% of women from our case/control
study nested in the Detroit BBD cohort were considered to have dense breasts, or BI-RADS
density C and D, while only 16.4% of Detroit screening cohort were considered to have dense
breasts. This finding mimics those from predominately white studies: 64% of women with BBD
from the Mayo clinic’s cohort52 were considered dense, while 43.3% of women from Breast Cancer
Screening Consortium (BCSC) 77 were considered dense. It is important to compare our study to
a screening cohort of primarily African American women as breast density measurements differ
by race51. As breast density is inversely correlated with BMI50 and obesity prevalence is higher in
African American women34, directly comparing our estimates to BCSC would bias the effect of
BBD on breast density towards null. The lower prevalence of extremely dense breasts in both
African American and European American women in the Detroit Screening cohort compared to
the prevalence in BCSC suggests that factors beyond race contribute to density differences
including differences in population or radiology practice by site. Prevalence of extremely dense
breasts in the Detroit Screening cohort more closely resemble prevalence estimates from
screening studies conducted in Pennsylvania51,78 and Vermont79.
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We did not detect a statistically significant association between BI-RADs density and
breast cancer in our nested study of the Detroit BBD cohort, though we were likely limited by
sample size as the effect estimates were within the range of prior studies. Most screening studies
in primarily European American or European women show strong associations between BI-RADS
density and breast cancer that are monotonically increasing, where the extremely dense category
increases odds of having breast cancer 4-6 times compared to the odds of entirely fatty
breasts45,46. We were able to detect statistically significant associations between BI-RADS density
and breast cancer in the Detroit Screening cohort. Surprisingly in the Detroit Screening cohort the
strongest increase in odds of breast cancer was associated with BI-RADS density C or
heterogeneously dense breasts rather than density D or extremely dense breasts; however, this
finding most likely reflects the limited sample (less than 3%) of extremely dense breasts in the
Detroit Screening cohort as the 95% confidence intervals for these odds ratios overlap. A similar
pattern where BI-RADS density C conferred the largest increase in odds of breast cancer was
estimated for African American women in the Carolina Breast Cancer Study (CBCS) 69 where less
than 10% had BI-RADS density D or extremely dense breasts.
The strengths of our study include a centralized assessment of all mammograms by our
radiologists for BI-RADS density, Tabár classification and our Complexity indicator. This is the
first study we know of that examines breast density and parenchymal patterns in African American
women with BBD. There are a few important limitations to this study including a restricted sample
size. We also primarily use qualitative measures in this study which are more likely to suffer from
low reproducibility due to inter- and intra-observer variability; however, BI-RADS and Tabár
reproducibility is relatively high74. We are also limited by risk factors we were unable to capture or
measure during data collection including body mass index (BMI). The missing information on BMI
in the Detroit BBD cohort limits the validity of comparisons between BI-RADS density and breast
cancer risk between the Detroit BBD and Detroit Screening cohorts.
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Our findings suggest there is clinical utility to assessing structural features on
mammogram for women with a history of BBD. The Breast Cancer Risk Assessment Tool15
considers women with a prior biopsy at increased breast cancer risk and these women
subsequently undergo increased surveillance, receiving mammograms every six months for two
years post biopsy. Improving risk assessment from these mammograms can limit further biopsies
that may result in unnecessary patient harms including stress, anxiety and pain. This study
warrants further study in a larger sample.
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CHAPTER 4: ADIPOSE INFLAMMATION AND THE RISK OF BENIGN AND MALIGNANT
BREAST DISEASE IN AFRICAN AMERICAN WOMEN
I. Introduction
Breast cancer incidence has been rising in African American women, who suffer a 40%
higher cancer specific mortality compared to European American women2,80. Despite this burden,
African American women are poorly represented in cohorts studying breast cancer risk factors.
Resulting breast cancer risk models, which physicians can use to determine patient surveillance
and preventative needs, underestimate risk in African American patients17,19. Among women of
all races, commonly used risk models cannot discriminate between women who will develop
breast cancer from women who will not with a high degree of accuracy at the individual level16.
Risk model accuracy improves with the inclusion of risk factors that capture biological information
associated breast cancer risk and carcinogenesis such as gene risk scores, breast density, and
benign breast disease (BBD)16.
Another risk factor that has not been widely incorporated into risk models is obesity, likely
because of its complex relationship with breast cancer risk. Obesity is associated with increased
breast cancer incidence in postmenopausal women, and is associated with triple negative breast
cancer in premenopausal women23,25. Several mechanisms may contribute to this increase,
including the peripheral aromatization of androgens to estrogens in adipose tissue depots which
increases postmenopausal estrogen exposure significantly and thus breast cancer risk 24,25.
Obesity has also been associated with increased breast adipose inflammation, exhibiting
adipocytes surrounded by macrophages, or crown-like structures of the breast (CLS-B) on light
microscopy81. Adipose inflammation may be independently associated with increasing breast
cancer incidence; inflammation has been associated with incidence of other cancers82,83. Breast
cancer risk models, including the Breast Cancer Risk Assessment Tool (BCRAT), currently do not
capture obesity and may improve by including this important risk factor16. While easy to ascertain,
body mass index (BMI) is a poor indicator of obesity84 and can misclassify African American
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women who have lower body fat and higher lean muscle mass than European American women
at a given BMI85,86. Adipose inflammation measures such as CLS-B may serve as better indicators
of a metabolically obese state.
Prior studies examining CLS-B in mastectomy tissue of breast cancer patients show that
adipose inflammation is associated with increasing BMI and post-menopausal status. In a study
of Caucasian, Latino and African American women with breast cancer, African American women
had the highest CLS-B counts, and increased CLS-B density was associated with poorer
progression-free survival87. Further studies utilizing breast cancer mastectomy tissue revealed
that CLS-B is also associated with mechanisms that increase estrogen in the breast
microenvironment including increased aromatase expression, activity, and an elevated local
estrogen to androgen ratio81,88; these results highlight a potential mechanism where adipose
inflammation may increase breast cancer risk. Another potential mechanism may stem from
wound healing responses that may occur with or after tissue inflammation; wound healing can
remodel tissue89. Remodeling of breast tissue could potentially lead to benign lesions seen on
non-malignant breast biopsies that increase subsequent breast cancer risk38. Carter et al90 is the
first study to examine whether CLS-B is associated with breast cancer risk by studying CLS-B
presence in non-malignant breast tissue from women with benign breast biopsies whose
subsequent breast cancer status was ascertained. This study found that the presence of five or
more CLS-B on biopsy was a significant risk factor for subsequent breast cancer90.
Adipose inflammation or CLS-B has not been well-described in normal tissue not from
surgery (reduction mammoplasty, prophylactic mastectomy or mastectomy tissue adjacent to a
tumor) or tissue from benign breast biopsies; furthermore, CLS-B has never been described in
such tissue from African American women. Studies of CLS-B in mastectomy tissue suggest CLSB presence differs in frequency by race87,91 thus characterizing adipose inflammation in diverse
populations is critical. Here we examined whether CLS-B is associated with risk of benign breast
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disease and breast cancer in African American women who suffer a higher incidence of breast
cancer, poorer breast outcomes, and a higher prevalence of obesity2,92.
II. Materials and Methods
Study design
We conducted a study utilizing a subset of the nested case/control study described in
Chapter 3 and additional age-matched controls from the Komen Normal Tissue Bank (KTB).
Our subset included women who developed invasive breast carcinoma and their age and year
of biopsy matched controls. Our main outcome of interest was breast cancer risk, where we
considered women from KTB as low risk, BBD controls as medium risk, and BBD cases as high
risk (as these women have developed invasive breast cancer). Our main exposure of interest
was adipose inflammation as assessed by CLS-B on breast biopsy; we identified CLS-B on
histology using a CD68 stain to mark the presence of macrophages. Associations between
CLS-B and breast cancer risk were then examined.
Study population
Study participants included three age-matched cohorts of African American women from
the Susan G. Komen Normal Tissue Bank (KTB) at the Indiana University Simon Cancer Center
and the Detroit BBD cohort53,93. KTB collects percutaneous needle biopsy breast tissue, blood,
and questionnaire data including BMI from healthy volunteer donors at collection events around
the country; 5% of KTB donors are African American93. Further details on the Detroit BBD cohort
are located in Chapter 2.
Three groups for this study in order of decreasing breast cancer risk included the BBD
cases, BBD controls, and Komen population controls. 55 African American women from the
Detroit BBD cohort without cellular atypia on benign biopsy, developed a subsequent invasive
breast cancer, and available BBD and tumor tissue were classified as BBD cases. 47 African
American women from the BBD cohort who had not developed invasive or in situ breast cancer
as of December 2016 and matched to the BBD cases on age and year of biopsy were classified

47
as BBD controls. An additional 50 African American women from the KTB with no self-reported
history of BBD or breast cancer were matched to BBD cases on age were classified as Komen
population controls. Komen population control biopsies were reviewed by our study pathologist
for Dupont and Page criteria39 and subsequently further divided by BBD presence on biopsy into
Komen Normal and Komen BBD groups for analysis. Komen BBD and BBD controls were
grouped together for several analyses as this group showed similar histological abnormalities that
confer increased breast cancer risk from normal tissue. Any Komen BBD or BBD controls that
showed cellular atypia on biopsy, a strong breast cancer risk factor, were excluded from analyses
to avoid bias. BMI close to the BBD date and prior to breast cancer diagnosis was ascertained
via medical record review for the Detroit BBD cases and controls. This study was approved by
the Institutional Review Board of Wayne State University.
Laboratory methods
Formalin-fixed paraffin embedded biopsy tissue from each study participant were serially
sectioned and deparaffinized in a xylene-ethanol series. Endogenous peroxides were removed
with a methanol/1.2% hydrogen peroxide incubation at room temperature for thirty minutes. HIER
antigen removal was completed with a pH 6 citrate buffer and the BIOCARE Decloacking
Chamber. A 40-minute blocking step with Super Block Blocking buffer (Thermo Scientific) was
performed prior to adding the primary antibody for CD68, DAKO #M0876, 1:100 dilution overnight.
Detection was obtained using GBI Labs DAB chromagen kit (#D41-18) and counterstained with
Mayer’s Hematoxylin. Sections were then de-hydrated through a series of ethanol to xylene
washes and cover slipped with Permount. Stained slides were assessed by pathologists for CLSB presence (see Figure 4). CLS-B number was assessed on digital images of slides. Adipose
area was calculated from digital images of Hematoxylin & Eosin slides using the Adiposoft plugin
from ImageJ94,95.

48

Figure 4. Adipose breast tissue stained for CD68, 5.0x magnification. 4 crown-like structures of the
breast, adipocytes surrounded by macrophages, are indicated by red arrows.

Statistical methods:
Our first objective was to examine whether the three risk groups (KTB, BBD Controls and
BBD Cases) differed by distribution of age, BMI, epithelial proliferation and cellular atypia at
biopsy. We described the distribution of these clinicopathologic characteristics using percentages
and evaluated potential differences with Pearson chi-square tests. Our second objective was to
examine whether breast cancer risk was associated with adipose inflammation. We evaluated this
association by estimating the odds of having breast cancer by CLS-B presence (or the presence
of 5 or more CLS-B, similar to study at Mayo Clinic90) using univariable and multivariable ordinal
logistic models using the logarithm of adipocyte area on biopsy as an offset variable. Our third
objective was to examine the association between breast cancer risk and adipose inflammation
in clinically-indicated biopsies (BBD Cases and Controls) in order to understand how this marker
could be used in future patient management this subgroup is more likely to reflect women biopsied
in the future. To evaluate this association, we estimated the odds of having breast cancer by
CLS-B presence (or 5 or more CLS-B) among BBD cases and controls using univariable and
multivariable conditional logistic regression models using the logarithm of adipocyte area on
biopsy as an offset variable and age as a stratification variable. Our last objective was to
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understand how the association between breast cancer risk and adipose inflammation may be
modified by BMI or epithelial proliferation, a risk factor in benign breast disease. We evaluated
these associations using Cochrane-Mantel-Haenzel trend tests.
III. Results
Clinicopathologic characteristics
The mean age of the study population was 54.0 years; mean age did not significantly differ
between study groups (p=0.52). Menopausal status by age did not differ significantly by group;
14.5% were categorized as premenopausal (age < 45), 43.4% were categorized as
perimenopausal (aged 45 to 55), and 42.1% were categorized as postmenopausal (age > 55,
Table 15). The mean BMI of the study population was 32.0; mean BMI did not differ between
study groups significantly (p=0.39). Over half of the study participants were considered obese
with a BMI greater than 30, so we examined the distribution among normal, overweight and
obesity classes I to III as defined by the World Health Organization96. Distribution of BMI classes
did not differ significantly by study group; 22% were normal weight, 24% overweight, 20% obese
class I, 18% obese class II, and 16% obese class III.
Histological review of the KTB Population Control biopsies revealed that 54% of the
biopsies did not show histologic abnormalities, or KTB Normal. Of the biopsies that showed
histologic abnormalities, or KTB BBD, 70% showed non-proliferative disease, 26% showed
proliferative disease and 4% showed proliferative disease with atypia. BBD controls and BBD
cases did not significantly differ in distribution of Dupont and Page criteria; 51% of the BBD tissue
showed non-proliferative disease. Distribution of epithelial proliferation was significantly lower
among KTB BBD than the BBD cases and controls (p<0.001), suggesting that asymptomatic BBD
is less likely to include proliferative disease on biopsy.
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Table 15. Clinicopathologic characteristics of African American women with breast biopsy tissue
from the Detroit BBD Cohort (1997-2010) and the Komen Normal Tissue Bank examined for the
presence of CLS-B
Overall
KTB
KTB BBD
BBD
BBD Cases
Normal
Controls
N (%)
N = 152
n = 27
n = 23
n = 47
n = 55
Age
<45 22 (14.5%)
6 (22.2%)
1 (4.3%)
7 (14.9%)
8 (14.5%)
45-55 66 (43.4%)
12 (44.4%)
10 (43.5%)
19 (40.4%)
25 (45.5%)
>55 64 (42.1%)
9 (33.3%)
12 (52.2%)
21 (44.7%)
22 (40.0%)
BMI
<25 32 (22%)
2 (7%)
7 (30%)
12 (26%)
11 (22%)
25 – 29 35 (24%)
7 (26%)
4 (17%)
8 (17%)
16 (31%)
30 – 34 30 (20%)
4 (15%)
4 (17%)
13 (28%)
9 (18%)
35 – 39 27 (18%)
11 (41%)
4 (17%)
6 (13%)
6 (12%)
40 + 23 (16%)
3 (11%)
4 (17%)
7 (15%)
9 (18%)
BBD
No histologic abnormalities 27 (17.8%)
27
-0
0
Non-proliferative disease 68 (44.7%)
-16 (69.6%)
24 (51.1%)
28 (50.9%)
Proliferative disease 55 (36.2%)
-6 (26.1%)
22 (46.8%)
27 (49.1%)
without atypia
Proliferative disease with 2 (1.3%)
-1 (4.3%)
1 (2.1%)
0
atypiaa
aBiopsies containing proliferative disease with atypia were excluded from further analyses

CLS-B and in breast tissue of varying risk
Overall, CLS-B were found in 61 of 143 (42.7%) of all study slides assessed. CLS-B were
more likely to be identified in tissue with higher breast cancer risk (12.5% KTB normal controls,
33.3% KTB BBD and BBD controls, 68.6% BBD cases, Table 16, unadjusted p-value<0.001).
KTB BBD and BBD controls were combined as these slides show histologic abnormalities on
biopsy that would indicate increased breast cancer risk from population level risk. The median
number of CLS-B in CLS-B positive slides did not differ significantly between groups (3, 2, and 5
for KTB normal, KTB BBD and BBD controls, and BBD cases, respectively), but the upper bound
of range varied widely among groups (4, 33, 109). Higher breast cancer risk was associated with
tissue that exhibited five or more CLS-B on biopsy (0% KTB normal controls, 9.1% KTB BBD and
BBD controls, 37.3% BBD cases, p-value<0.001).
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Table 16. Crown-like structures of the breast and breast cancer risk among all breast biopsy
tissue from African American women in the Detroit BBD Cohort (1997-2010) and the Komen
Normal Tissue Bank
KTB Normal KTB BBD and
BBD Cases
OR
OR
BBD Controls a
(95% CI) b
(95% CI) c
CLS-B (any)
3 (12.5%)
22 (33.3%)
35 (68.6%)
5.87
3.34
(2.94 – 12.1)
(1.58 – 7.38)
0
6 (9.1%)
19 (37.3%)
8.82
6.59
CLS ≥5
(3.45 – 25.9)
(2.27 – 21.7)
Median (range) 3 (1-4)
2 (1-33)
5 (1-109)
bKTB BBD and BBD controls were combined as these show histologic abnormalities that indicate
increased breast cancer risk
bP-value from ordinal logistic regression unadjusted for other factors.
cP-value from ordinal logistic regression adjusted for the logarithm of adipocyte area and BMI.

The presence of CLS-B on biopsy was associated with a 5.87 times increased odds of
being in a higher-risk tissue category in this study (95% Confidence Interval (CI): 2.94 – 12.1,
Table 16). After adjusting for total adipocyte area and BMI, this association was attenuated with
a 3.34-fold increased odds of being in a higher-risk tissue category that was statistically significant
(95% CI: 1.58 – 7.38). The presence of five or more CLS-B on biopsy was associated with a 8.82fold increased odds of being in a higher-risk tissue category (95% CI: 3.45 – 25.9). Similarly, once
adjusting for total adipocyte area and BMI, the association between the presence of five or more
CLS-B on biopsy was attenuated to a 4.81-fold increased odds of being in a higher-risk tissue
category (95% CI: 2.27 – 21.7).
Among the subset of women with a clinical indication for biopsy, or the BBD controls and
BBD cases from the Detroit cohort, CLS-B were more likely to be identified in BBD case than BBD
control tissue (68.6% versus 37.8%, Table 17, p-value = 0.004). BBD cases were also more likely
to have five or more CLS-B on tissue slides than BBD controls (37.3% to 11%, p-value = 0.007).

Table 17. Crown-like structures of the breast and breast cancer risk among benign breast biopsies
from African American women from the Detroit BBD Cohort, 1997-2010
BBD Controls BBD Cases
OR (95% CI)b
OR (95% CI)d
CLS-B (any)
17 (37.8%)
35 (68.6%)
3.50 (1.50 – 8.19)
2.94 (1.12 – 7.73)
CLS ≥5
5 (11.1%)
19 (37.3%)
4.45 (1.51 – 13.1)
3.78 (1.17 – 12.2)
Median (range)
2 (1-33)
5 (1-109)
aP-value from conditional logistic regression unadjusted for other factors.
dP-value from conditional logistic regression adjusted for the logarithm of adipocyte area, proliferative
disease, and BMI
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Among clinically-indicated biopsies, the presence of CLS-B on biopsy conferred a 3.50fold increased odds of breast cancer (95% CI: 1.50 – 8.19; Table 17); adjusting for total adipocyte
area, BBD and BMI attenuated this increase to 2.94 times increased odds (95% CI: 1.12 – 7.73).
The presence of five or more CLS-B on clinically-indicated biopsy conferred a 4.45-fold increase
in odds of breast cancer (95% CI: 1.51 – 13.1); adjusting for total adipocyte area, BBD and BMI
attenuated this association to a 3.77-fold increased odds of breast cancer (95% CI: 1.17 – 12.20).
CLS-B and breast cancer risk, adjusting for BMI and/or BBD
CLS-B was not associated with BMI in the overall study; the proportion of CLS-B positive
biopsies varies slightly between BMI categories but with no apparent pattern. CLS-B positive
biopsies were found in 40% of normal weight women, 41% of overweight women, 33% of obese
class I women, and 49% of obese class II & III women (Table 18, p-value=0.2082). CLS-B
presence was associated with increasing breast cancer risk among each BMI group (pvalue<0.001). The proportion of CLS-B positive biopsies remained consistent among BMI groups
in both the KTB Normals and BBD Cases. The proportion of CLS-B positive biopsies increased
in KTB BBD/BBD controls with increasing BMI (22% in normal weight to 64% in obese class III).

Table 18. Crown-like structures of the breast and breast cancer risk adjusting for BMI among
breast biopsy tissue from African American women from the Detroit BBD Cohort (1997-2010) or
the Komen Normal Tissue Bank
Overall
KTB Normal
KTB BBD and BBD Cases
BBD Controls
N (%) with any CLS-B
N = 139
n = 24
n = 66
n = 49
BMI <25
12/30 (40%)
0/1
4/18 (22%)
8/11 (73%)
BMI 25 – 29
13/32 (41%)
1/6 (17%)
3/11 (27%)
9/15 (60%)
BMI 30 – 34
10/30 (33%)
0/4
5/17 (29%)
5/9 (56%)
BMI 35+
23/47 (49%)
2/13 (15%)
11/20 (55%)
10/14 (71%)

CLS-B was present more frequently in biopsies with proliferative disease compared to
biopsies with non-proliferative disease, but this difference was not statistically significant (59%
versus 41%, p-value>0.1, Table 19). CLS-B presence was associated with increasing breast
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cancer risk among each proliferative group (p-value=0.002). CLS-B frequency differed more
between BBD cases and KTB BBD/BBD controls in biopsies showing non-proliferative disease
(64% versus 26%) than biopsies with proliferative disease (70% versus 48%).

Table 19. Crown-like structures of the breast and breast cancer risk adjusting for BBD among
breast biopsy tissue from African American women with breast biopsy tissue from the Detroit
BBD Cohort (1997-2010) or the Komen Normal Tissue Bank
Overall
KTB BBD and
BBD Cases
BBD Controls
N (%) with any CLS-B
N = 117
n = 65
n = 52
Non-proliferative disease
26/63 (41%)
10/38 (26%)
16/25 (64%)
Proliferative disease
32/54 (59%)
13/27 (48%)
19/27 (70%)
without atypia

IV. Discussion
Our findings demonstrate that CLS-B is associated with risk of both BBD and breast
cancer. After adjusting for BMI and BBD, CLS-B was independently associated with breast cancer
risk in this study of biopsy tissue from African American women with benign breast disease. These
data suggest that CLS-B is a candidate biomarker on histology for breast cancer risk among
women with benign breast disease, and these lesions may provide additional insight into early
events to carcinogenesis.
Our study found a stronger association between presence of CLS-B and breast cancer
risk among clinically-indicated biopsies (p-value = 0.028) than a prior study published by Carter
et al90 (p-value = 0.11). Carter el al found similar trends between CLS-B presence between normal
and BBD tissue, but a more specific metric of five or more CLS-B on biopsy was necessary to
discriminate between BBD controls and cases. The difference in association may be due to
differences between study cohorts. The cohort described in Carter et al primarily consists of
European American women, while ours consists of African American women. Prevalence of
obesity is higher in African American women compared to European American women92, and a
recent study of CLS-B in mastectomy tissue indicates that CLS-B presence is also elevated in
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African American women compared to Hispanic and European American women87. Additionally,
the study cohort in Carter et al was diagnosed with BBD between 1967 and 2001, while the Detroit
cohort is a more contemporary cohort diagnosed between 1997 and 2010. Obesity prevalence
has steadily increased since the 1960s97 and other changes in reproductive or hormonal
exposures over time may contribute to the stronger results in our study.
Contrary to other studies81,88,90,91,98–100, CLS-B was not associated with BMI in our study.
This discrepancy may arise because of the reduced utility of BMI as a measure of adiposity in this
population: African American women have lower body fat compared to European American
women at the same BMI85,86. Only one other CLS-B study had a sample size large enough for
race-specific estimates in African American patients, but Koru-Sengul et al was unable to test for
an association with BMI as patient heights were not collected87. Our study design may contribute
to this null finding; we may have been unable to detect an association with the limited sample size
of this study. We also examined one CD68-stained slide per patient to determine CLS-B status,
while several other CLS studies81,91,98,99 examined five slides per patient.

From a clinical

perspective, it is more feasible to examine a single representative slide, so future studies should
consider this protocol. Increases in adipose tissue area assessed most likely increases the
likelihood of finding a CLS-B. A majority of CLS-B studies81,87,88,91,98–100 utilize mastectomy or
prophylactic mastectomy tissue, which reflects extremely high-risk tissue that may be enriched
for CLS-B compared to our study tissue of normal and BBD tissue from the Komen Normal Tissue
Bank and Detroit Cohort. Other CLS-B studies were able to utilize reduction mammoplasty
tissue101, but this tissue is more likely to exhibit benign breast lesions and less likely to exhibit
lobular involution on microscopy than KTB normal population-level risk tissue102.
Strengths of our study include the use of population-level controls and a contemporary
cohort of African American women diagnosed with BBD and subsequently followed for breast
cancer to assess the relationship between CLS-B and breast cancer risk. Additionally, our study
included the use of normal controls by identifying tissue from KTB free from histologic
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abnormalities as well as a contemporary cohort of African American women diagnosed with BBD
and subsequently followed for breast cancer to assess the relationship between CLS-B and breast
cancer risk. Another strength is the ease of translating this approach to the clinic. Our results
suggest that staining only one additional slide for CD68 can provide valuable information on
breast cancer risk. Limitations of our study include the limited sample size and tissue area
assessed, but these did not hinder us from detecting a relationship between CLS-B and breast
cancer risk independent of age, BMI and BBD. Another potential limitation is that we do not have
information on several other breast cancer risk factors including age at menarche, parity, BRCA
status, and family history that may confound the relationship between CLS-B and breast cancer
risk. Examination of the tissue may compensate somewhat for this limitation, as the tissue
represents the totality of exposures.
Currently, the standard of care for women with biopsies that contain cellular atypia
requires a more extensive surgical excision and consideration of chemopreventative efforts and
increased surveillance because these lesions are more likely to be near a synchronous breast
cancer and are associated with the greatest risk of a subsequent breast cancer38. However,
approximately 95% of women with BBD who develop breast cancer have non-proliferative or
proliferative disease without atypia on biopsy38. Refining our understanding of breast cancer risk
can allow us to personalize surveillance and prevention efforts. CLS-B could be used to better
identify patients exhibiting metabolic obesity who are poised to benefit greatly from behavioral
changes or surveillance.
Additional studies must be completed before CLS-B can be used as a histological marker
of breast cancer risk. This risk associated with this structure needs to be validated in a larger
cohort, and while quite distinct, formal studies of pathologic reproducibility are also warranted.
Our study and a few others in mastectomy tissue87,91 suggest there may race-specific nuances to
the relationship between CLS-B and risk of a subsequent breast cancer, and point to the
importance of diverse and contemporary cohorts to characterize breast cancer risk factors.
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CHAPTER 5: CONCLUSIONS
Summary of Findings
The results of this dissertation show that breast cancer risk factors vary by race. In Aim 1
fibroadenomas were associated with a reduced risk of breast cancer compared to all other BBD
on biopsy in the Detroit BBD cohort. When compared to other African American women in Detroit,
women with fibroadenomas on biopsy were not at elevated breast cancer risk. In Aim 2 we found
similar associations between breast density and breast cancer in both the Detroit BBD cohort and
Detroit Screening cohort to previous reports. We found that African American women with BBD
were more likely to have dense breasts than African American women without BBD, consistent
with prior studies in European American women. Nodular patterns, assessed by Tabár and our
radiologists’s complexity indicator, were strongly associated with breast cancer in the Detroit BBD
cohort. In Aim 3, CLS-B was independently associated with breast cancer risk, and the effect size
was greater in our study of African American women than a prior report of European American
women.
Future directions
Each chapter in this dissertation has clear next steps or subsequent lines of thought to
examine. In Aim 1, fibroadenomas could be further examined for features that would make these
benign tumors complex such as cysts, apocrine metaplasia, calcifications and sclerosing
adenosis. The presence of these features indicates that the fibroadenoma is complex and may
confer increased risk compared to fibroadenomas uncomplicated by the lesions59.
In Aim 2, quantitative measures of breast density from our study mammograms at the time
of biopsy could examined for an association with breast cancer risk. Serial mammograms
spanning the time of biopsy to breast cancer diagnosis or end of follow-up could also be examined
for women in our study to assess whether there are any changes in temporal trends of quantitative
or qualitative density or parenchymal patterns. Further gene expression study from the nested
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case/control study could also be used to assess whether there are gene expression patterns that
are associated with density or parenchymal patterns.
In Aim 3, other outcomes could be assessed in our study, including inflammation on biopsy
measured by lymphocyte infiltration and adipocyte size on H&E slides. These outcomes could be
tested for associations with BBD, BMI, and CLS-B on biopsy. The design of Aim 3 sampled
women from the nested case/control study in Aim 2, so associations between CLS-B and breast
density or parenchymal patterns could be assessed. Similarly, gene expression patterns
associated with CLS-B on biopsy could be examined.
Conclusions
Before the risk factors described in this publication can be incorporated into risk models,
these findings must be replicated in prospective cohorts of African American women as well as
women of other ethnicities to validate for subsequent use. Consistent, replicable risk factors are
critical to inform appropriate clinical management. Risk model utility can be improved by creating
subtype-specific breast cancer risk models. Current models describe risk of ER positive tumors
which respond well to treatment and have better prognosis that ER negative tumors31; yet it is the
more aggressive, often ER negative, cancers that would likely benefit most from risk prediction.
These tumors that rapidly progress and quickly prove fatal tend to occur more frequently in African
American women9.
The studies included in this dissertation showed that breast cancer risk estimates may
vary with time, race, and site of the population studied. These studies also illustrated the potential
for novel markers of risk on mammogram and biopsy, suggesting that we are not effectively using
current screening tools. Annually, about 40 million women undergo screening mammography and
1.6 million women undergo a breast biopsy in the United States37. Precision medicine has great
potential to improve population health, but current screening tools and technology also have great
untapped utility, at potentially at far less cost. Current screening methods must continually to be
assessed as predictive and prognostic markers across the continuum.
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ABSTRACT
CHARACTERIZING NOVEL RADIOLOGIC AND PATHOLOGIC TISSUE-BASED RISK
FACTORS FOR BREAST CANCER IN AFRICAN AMERICAN WOMEN WITH BENIGN
BREAST DISEASE
by
ASRA N. SHAIK
August 2018
Advisor: Dr. Michele L. Cote
Major: Cancer Biology
Degree: Doctor of Philosophy
African American women (AAW) suffer a higher breast cancer mortality burden than
women of other ethnicities in the US. More likely to be diagnosed with aggressive subtypes
resistant to therapy and with rapidly fatal course than European American women (EAW), AAW
may benefit greatly from earlier detection of breast cancers. However, it remains difficult to predict
with a high degree of accuracy which women will develop breast cancer. Current risk assessment
is especially poor for AAW, where models consistently underestimate risk in the subset of women
with a prior biopsy. Risk assessment can be improved with the inclusion of new risk factors and,
for AAW, race-specific estimates of risk factors. Here we characterized current and novel
radiologic and pathologic tissue-based risk factors to improve risk assessment in an understudied
population.
We utilized the Detroit BBD cohort to examine several risk factors. We first assessed
subsequent breast cancer risk associated with fibroadenomas, a previously-described risk factor.
In a nested case/control study, we assessed whether previously-described BI-RADS density
scores and Tabár patterns were associated with breast cancer. We also examined whether a
complexity indicator, summarizing features routinely described on mammogram but not yet
examined as a risk factor, was associated with breast cancer. Finally, in a subset of the nested
case/control study additionally age-matched to population-level controls, we examined whether
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crown-like structures of the breast (CLS-B) were associated with breast cancer risk. We used
several uni- and multivariable logistic, ordinal logistic, and conditional logistic models to estimate
associations between risk factors and breast cancer.
In Aim 1, fibroadenomas on biopsy were not associated with a breast cancer risk increase
over population level risk, unlike prior studies in EA women. In Aim 2, nodular patterns on
mammogram, assessed by Tabár classification or our complexity indicator, were strongly
associated with breast cancer. These findings suggest that AAW with BBD may benefit from
additionally assessing parenchymal patterns on mammography. In Aim 3, we found that CLS-B
was associated with breast cancer independent from BMI and BBD and may serve as a histologic
marker of risk. These findings suggest differences in risk by race, though we cannot rule out
secular differences between our contemporary cohort and other cohorts. These dissertation
results, once replicated in other studies, can inform risk assessment tools to better identify women
at increased breast cancer risk who may benefit from increased surveillance or chemoprevention.
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